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SUMMARY  
 
Erythropoietic protoporphyria (EPP, OMIM 177000) is a hereditary disease characterized by extreme-
ly painful photosensitivity. The underlying defect is a partial deficiency of the enzyme ferrochelatase 
(FECH) which catalyzes the last step of heme biosynthesis, the insertion of ferrous iron into 
protoporphyrin IX (PPIX). As a result of the enzyme deficiency, a large amount of the phototoxic sub-
stance PPIX accumulates in precursors of erythrocytes. In addition, up to 60% of EPP patients show 
disturbances of iron metabolism, e.g. microcytic, hypochromic anemia, low transferrin saturation and 
low ferritin. However, administration of iron is observed to worsen the photosensitivity. Genetically, 
over 97% of EPP patients carry, in addition to a loss of function mutation in trans, the identical SNP 
FECH IVS3-48C which enhances aberrant splicing. Since iron - and heme metabolism as well as 
splicing are highly regulated we hypothesized that a mechanism exists interconnecting the three pro-
cesses. An in-depth characterization of FECH intron 3 was performed to identify possible sequence 
features that may be related to the disease causing splice defect or respond directly or indirectly to 
iron, heme or other products and substrates of heme metabolism. We could show that two 
homopolymeric tracts in FECH intron 3 differ in length between individuals, and that the low expres-
sion allele IVS3-48C is associated with longer poly-C tracts. Although homopolymeric tracts are con-
served and significantly over-represented in the genome than simply by chance, we could not find a 
correlation between disease features and the length of these sequences yet. However, we could demon-
strate that cultured cells derived from patients and healthy controls show enhanced aberrant splicing of 
FECH intron 3 and a subsequent decrease of the amount of FECH protein under iron depletion. The 
effect is more pronounced in the more frequent SNP IVS3-48T. In the low expression allele (IVS3-
48C), a higher baseline level of aberrant splicing is seen under iron saturated condition, which is less 
enhanced by iron depletion. The consequence of an IVS3-48C genotype is therefore equivalent to the 
effect iron depletion exerts on cells from individuals with the more common genotype. The observed 
effect is mediated by the iron and 2-oxoglutarate-dependent dioxygenase Jmjd6, acting as a link be-
tween iron availability and splice regulation. To elucidate systemic aspects of iron metabolism in EPP, 
we further tested our hypothesis that the rate limiting enzyme of erythroid heme biosynthesis, 5-
aminolevulinic acid synthase 2 (ALAS2), is involved in the adverse reaction on iron supplementation 
observed in patients. ALAS2 mRNA harbors an iron-responsive element (IRE) which prevents transla-
tion of the enzyme in case iron is scarce. Since iron is deficient in most EPP patients, the translation of 
ALAS2 mRNA might be partly repressed. Consequently, administration of iron could lead to an in-
crease in ALAS2 protein due to a de-repression of the translation block and subsequently stimulate 
synthesis of PPIX, worsening the photosensitivity. In a longitudinal study, a positive correlation be-
tween hemoglobin levels and PPIX was seen in the three patients investigated – demonstrating the de-
pendence of both PPIX and heme synthesis on iron availability in EPP. Moreover, by investigating the 
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expression of ALAS2 in peripheral blood cells of EPP patients, we found a significant increase in 
ALAS2 protein and mRNA compared to healthy controls, amplifying the proposed effect and support-
ing the hypothesis of an involvement of ALAS in the etiology of EPP.  
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SUMMARY FOR LAYPERSONS IN GERMAN  
 
Erythropoietische Protoporphyrie (EPP) ist eine seltene, angeborene Lichtkrankheit bei der schon we-
nige Minuten an der Sonne oder sogar künstlichem Licht ausreichen, um extreme Schmerzen an allen 
unbedeckten Hautstellen auszulösen. Da das sichtbare Licht Verursacher der Symptome ist, helfen 
Sonnencreme und andere Massnahmen zum Schutz vor UV-Strahlung nicht. Hintergrund der EPP ist 
eine Störung der Herstellung des roten Blutfarbstoffs, bei der Eisen nicht optimal verwertet werden 
kann. Dadurch kommt es zum einen zu einer Anreicherung von Vorläuferstoffen des roten Blutfarb-
stoffs, die nicht weiterverarbeitet werden können und sich im Körper anreichern. Diese können mit 
Licht reagieren und verursachen tief in der Haut liegende Verbrennungen und Schäden an den Blutge-
fässen. Zum anderen wird vom Körper zu wenig roter Blutfarbstoff  hergestellt, was eine Blutarmut 
hervorruft. Die Ergebnisse von Laboruntersuchungen zur Blutarmut weisen darauf hin, dass dem Kör-
per Eisen fehlt. Paradoxer Weise reagieren viele Betroffene nach der Einnahme von Eisen allerdings 
mit einer Verschlimmerung der Lichtempfindlichkeit. In der vorliegenden Arbeit wurde untersucht, in 
welcher Weise Eisen Einfluss auf die Symptome der EPP nehmen kann. Wir konnten feststellen, dass 
die Einnahme von Eisen die Menge an Vorläufersubstanz nicht verringert, sondern im Gegenteil sogar 
erhöht, was die gesteigerte Lichtempfindlichkeit erklären würde. Der Grund liegt in einer Besonder-
heit bei der Herstellung des roten Blutfarbstoffs: Je mehr Eisen im Körper vorhanden ist, desto mehr 
Vorläuferstoffe werden bereitgestellt, um so viel wie möglich roten Blutfarbstoff herstellen zu können. 
Bei EPP allerdings kann das Eisen am Ende des Herstellungsweges nicht verwendet werden, so dass 
der zu viel bereit gestellte Vorläuferstoff ungenutzt bleibt und sich anreichert. Ein interessantes Resul-
tat unserer Untersuchungen war zudem, dass die Produktion der Vorläuferstoffe bei EPP generell an-
geregt ist, vermutlich wegen des chronischen Mangels an rotem Blutfarbstoffs. Eine Überproduktion 
an Vorläuferstoff wird durch einen molekularen Schalter verhindert,  solange wenig Eisen im Körper 
vorhanden ist. Wird allerdings Eisen eingenommen, ist diese Blockade gelöst und es kommt zur mas-
senhaften Herstellung von Vorläufersubstanzen – die dann wegen der Eisenverwertungsstörung nicht 
zu rotem Blutfarbstoff fertiggestellt werden können.  
Ein anderes Ergebnis unserer Untersuchungen zeigt allerdings, dass auch zu wenig Eisen einen negati-
ven Effekt bei EPP haben kann: Wir haben herausgefunden, dass Eisen noch an einer anderen Stelle 
die Menge des hergestellten roten Blutfarbstoffs reguliert. Ist an dieser Stelle zu wenig Eisen vorhan-
den, wird weniger zelleigene Maschinerie zur Herstellung des roten Blutfarbstoffs bereitgestellt. Die-
ser Mechanismus ist ein Beispiel dafür, dass Zellen sehr sparsam mit den vorhandenen Ressourcen 
umgehen. Für Menschen mit EPP bedeuteten unsere Resultate zusammengenommene, dass sowohl zu 
wenig als auch zu viel Eisen im Körper schaden können. Um das richtige Mass an Eisen für EPP-
Patienten zu finden, müssen noch einige Fragen durch die Forschung beantwortet werden.  
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I. INTRODUCTION 
 
1. Heme Biosynthesis 
Heme is an integral component of many proteins and is therefore essential for every human cell. 
Around 80 % of the total body heme is produced during erythropoiesis for the synthesis of 
hemoglobin1;2. Another 15 % of heme is required for the synthesis of cytochrome P450 class enzymes 
in the liver. Furthermore, heme is also necessary for a variety of other hemoproteins such as myoglo-
bin, neuroglobin, cytoglobin, oxidases, hydroxylases, peroxidases like catalase and thyreoperoxidase 
and the cytochromes necessary for electron transfer in the respiratory chain in mitochondria3.  
The biosynthesis of heme takes place in every nucleated cell, but is differently regulated in erythropoi-
esis in contrast to ubiquitous synthesis3. The pathway consists of eight enzymes that sequentially con-
vert glycine and succinyl-coenzyme A (succinyl-CoA) to heme. The first step occurs in the 
mitochondrium, where the enzyme 5-aminolevulinate synthase condensates succinyl-CoA and glycine 
to form 5-aminolevulinic acid (ALA), the exclusive precursor of heme biosynthesis. The enzyme has 
two isozymes, the housekeeping 5-aminolevulinic acid synthase 1 (ALAS1) and the erythroid 5-
aminolevulinic acid synthase 2 (ALAS2), that are encoded by different genes and cannot compensate 
for each other. The next four biosynthetic steps take place in the cytosol. Two molecules of ALA are 
condensated by delta-aminolevulinate dehydratase (ALAD) to give rise to the monopyrrol 
porphobilinogen (PBG). Four molecules of PBG are joined to form the tetrapyrrol 
hydroxymethylbilane (HMB) by the cytosolic enzyme hydroxymethylbilane synthase (HMBS), also 
known as porphobilinogen deaminase (PBGD). Subsequently, the linear HMB is closed to form a cir-
cular molecule, uroporphyrinogen III by uroporphyrinogen III synthase (UROS). Additionally, the en-
zyme inverts one of the pyrrols (D-ring). Non-enzymatic cyclisation of HMB may also occur, however 
the product, uroporphyrinogen I, has no biological function and is excreted in the urine. 
Uroporphyrinogen III is converted to coproporphyrinogen III by the enzyme uroporphyrinogen III de-
carboxylase (UROD) which removes the acetic acid side chains of the molecule. The propionate 
groups of two pyrrols are then decarboxylated by the enzyme coproporphyrinogen III oxidase 
(CPOX). This reaction takes place in the inter-membrane space of the mitochondrium and results in 
protoporphyrinogen IX which is then oxidized by the enzyme protoporphyrinogen oxidase (PPOX), 
located at the outer surface of the inner mitochondria membrane, to form protoporphyrin IX (PPIX). 
Finally, the enzyme ferrochelatase (FECH) inserts ferrous iron into protoporphyrin IX to form heme. 
Mutations in each of the biosynthetic enzymes except ALAS1 are associated with the genetic diseases 
of porphyrias which will be discussed in detail in Chapter III 3-5.  
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2. Regulation of heme biosynthesis 
 
Excess heme is toxic to the body and excess porphyrinogens spontaneously oxidize to porphyrins that 
have no biologic function in the mammalian organism but can act as endogenous photosensitizers 3. 
The metabolism of heme is therefore tightly regulated in order to meet the requirements of the body 
but prevent the accumulation of toxic intermediates and products of heme synthesis and catabolism 
3;6;7. The regulation of heme biosynthesis is mainly achieved by the first and rate-limiting enzyme of 
the pathway, 5-aminolevulinate synthase, which has a housekeeping (ALAS1) and an erythroid-
specific (ALAS2) isoform 8;9. The expression of both enzymes show distinct regulatory features and 
will be discussed in depth in this chapter. ALAS1 and ALAS2 are coded by two separate genes, located 
on chromosome 3 and X, respectively 10;11. The rest of the enzymes are encoded by a single gene. If 
isoforms are present, they are generated by alternative splicing under the control of distinct erythroid-
specific and house-keeping promoters 5. Ferrochelatase (FECH) is the last enzyme of the pathway and 
inserts ferrous iron into PPIX to form heme. As key enzymes of heme biosynthesis in the disease 
erythropoietic protoporphyria (EPP), the regulation of ALAS1, ALAS2 and FECH are described in de-
tail in the sections below. Heme degradation is controlled by the enzyme heme oxygenase-1 (HO-1), 
the rate limiting enzyme of heme catabolism 12. HO-1 cleaves the porphyrin ring, and subsequently, 
the pyrrol is degraded to bilirubin, carbon monoxide and free iron, which is reutilized by the body. 
HO-1 is induced by heme and its derivate hemin 13;14. Heme synthesis can be limited either by reduced 
iron availability as the result of nutritional iron deficiency or because of underlying defects of iron ac-
quisition 15. Alternatively, the synthesis of heme can be impaired by defects in genes necessary for 
heme biosynthesis leading to one of the forms of inherited porphyrias (see Chapter III and Anderson et 
al. 2001 3). Accumulation of heme precursors may also be a result of intoxication with substances in-
terfering with heme biosynthetic enzymes like lead 16;17, high concentrations of iron 18, viral infections 
of the liver 19 or xenobiotics like hexachlorobenzene, a toxic ingredient of a fungicide causing an epi-
demic intoxication in Turkey in the 1950s 20.  
 
2.1. Regulation of ALAS1  
ALAS1 is the rate limiting enzyme of the housekeeping heme biosynthesis. The enzyme is a 71 kDa 
protein of 640 amino acids in length. It is active as a homodimer but requires pyridoxal 5-phosphate 
(PLP) as cofactor and is located in the mitochondrial matrix 5;21. The most important site of expression 
is the liver, where around 15% of the heme biosynthesis takes place. The expression of ALAS1 is con-
trolled by the end-product heme via a negative feedback mechanism. Excess heme binds to three heme 
regulatory motifs (HRM) present in the amino-terminal end of ALAS1 and prevents the protein from 
being imported into the mitochondrium 22;23. Additionally, heme decreases the amount of ALAS1 
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mRNA in liver cells by suppressing transcription and reducing its half-life 24-26. Two alternative splice 
forms exists, a more abundant in which an alternative exon 1A is joined to exon 2 and shows sensitivi-
ty to heme, and a less abundant  mRNA form containing exon 1B, which renders the protein insensi-
tive to inhibition by heme 26-28. Heme also has been shown to induce the degradation of ALAS1 en-
zyme by Lon Peptidase 1 (LONP1) in the mitochondrium 29. ALAS1 expression is induced by heme 
deficiency and a plethora of factors and molecular mechanisms extensively reviewed by Thunell 
(2006) 30. Xenobiotics, glucose deficiency, fasting, stress and hormonal factors increase ALAS1 ex-
pression by several folds, making it the main therapeutic target for the treatment of acute porphyrias 
(see Chapter III). Acute porphyric crises are treated with glucose or preferably with hemin or heme 
arginate in order to down regulate the activity of ALAS1 30.  
 
2.2. Regulation of ALAS2  
The gene coding for ALAS2 is located at position Xp11.21 and consists of 11 exons 10;31. ALAS2 con-
tains an amino-terminal targeting signal peptide for transport into the mitochondrial matrix, which is 
cleaved during transport 32. The enzyme consists of 587 amino acids and the mature enzyme has a mo-
lecular weight of 60 kDa. The precursor containing the targeting sequence has a weight of 65 kDa. 
ALAS2 acts as a homodimer and the activity is PLP dependent; additionally, PLP increases the stabil-
ity of the enzyme 33;34.  Lathrop (1993) identified heme binding motifs in the amino-terminal end of 
ALAS2, which seems to have lost its regulatory function22. In ALAS1, the same motifs are found 
which prevents the protein from import into the mitochondrium when heme is bound 22;23. 
ALAS2 is only expressed during erythropoiesis and found in erythroid precursor cells in the bone mar-
row, in reticulocytes and young erythrocytes in the blood. During embryogenesis, ALAS2 is present in 
fetal liver cell 11. The transcription of ALAS2 is regulated by transcription factors binding to sequence 
elements in the promoter region or to enhancer elements, like GATA1, SP1 and TATA binding protein 
(TBP) 35-38. Putative binding sites for the erythroid specific transcription factors GATA1, NF-E2 and 
EKLF have been identified by Kramer et al. 39, which however do not sufficiently explain the exclu-
sive expression of the enzyme during erythropoiesis. Intron 8 possesses a strong, orientation-
dependent sequence element including GATA1 binding sites and CACCC boxes binding GATA1 and 
SP1 in vitro, which enhances erythroid transcription 31. Han et al. (2006) demonstrated that histone 
acetyltransferase p300/CBP binds to the ALAS2 promoter and synergistically enhances ALAS2 mRNA 
transcription with transcription factor SP140. The expression of ALAS2 is also known to be positively 
influenced by the presence of heme 41. 
Hofer et al. (2003) showed that hypoxia induces ALAS2 mRNA up-regulation, but not by a putative 
hypoxia inducible factor 1 (HIF1) binding site in the promoter of ALAS2 42. Kaneko et al. (2009) noted 
that under hypoxic conditions, transforming growth factor-beta1 (TGF-beta1) is over-expressed in 
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YN-1 human erythroid precursor cells 43. Exogenous TGF-beta1 signaling enhanced the expression of 
ALAS2 mRNA. Therefore they concluded that hypoxia mediated TGF-beta1 up-regulation but not 
HIF1, which in turn induces ALAS2 mRNA expression. On the contrary, Zhang (2011) identified 
three binding sites for HIF1 downstream of the ALAS2 gene, which bind HIF1 under hypoxic condi-
tions and increase the expression of ALAS2 mRNA and protein 44. Hypoxia was described to influ-
ence the stability of ALAS2 protein: Abu-Farah (2005) demonstrated that in the human 
erythroleukemic K562 cell line hypoxic conditions stabilize ALAS2 protein by inhibition of degrada-
tion by the proteasome 45.  
Hemoglobin biosynthesis and iron metabolism are connected by the regulation of ALAS translation: 
The 5’-untranslated region (5`UTR) of ALAS2 mRNA contains an iron-responsive element (IRE), that 
acts as a binding site for iron regulatory protein 1 and 2 (IRP 1 and IRP 2). IRP 1 possesses a [4Fe-4S] 
iron-sulfur cluster and if iron is present, IRP 1 acts as a cytoslic aconitase that converts citrate to 
isocitrate 46. IRP 2 is degraded under iron saturated conditions. Conversely, a low-iron content leads to 
the binding of IRP 1 or 2 to the IRE which then blocks the translation of ALAS2 mRNA and in turn 
reduces the amount of active enzyme 7;47;48. In the absence of iron, less heme precursors are built. 
Loss-of-function mutations in ALAS2 lead to X-linked sideroblastic anemia (XLSA; OMIM 300751), 
characterized by anemia, iron accumulation and ringed sideroblasts. As learned from XLSA patients, 
ALAS1 cannot compensate for reduced ALAS2 activity. Carboxy-terminal mutations in ALAS2 lead 
to disruption of the binding of the beta-subunit of succinyl-CoA synthetase (SUCLA2), which reduces 
the activity of the enzyme and cause XLSA 49. A number of modifying genes are known to influence 
ALAS2 activity: Ye (2010) identified a patient with sideroblastic anemia with a mutation in the 
glutaredoxin 5 (GLRX5) gene, with impairments in iron-sulfur cluster biogenesis and lack of cytolsolic 
iron and decreased amount of ALAS2 protein, promoted by IRP mediated translational repression 50. 
Vice versa, the amount of ALAS2 was shown to be increased in IRP 2 -/- and IRP 2-/- IRP 1 +/-  
knockout mice 51. 
Recently, gain-of-function mutations in ALAS2 have been detected, leading to X-linked dominant 
protoporphyria (XLDPP; OMIM 300752). XLDPP is characterized by the accumulation of huge 
amount of protoporphyrin IX (PPIX) and zinc-protoporphyrin (Zn-PPIX) during erythropoiesis and a 
phenotypical presentation resembling the symptoms of EPP 52;53. Gain-of-function mutations in ALAS2 
were also described to worsen the phenotype in one case of congenital erythropoietic porphyria (CEP), 
were it acts as a modifier gene 54.  
 
2.3. Regulation of FECH  
FECH is the last enzyme of the heme biosynthesis pathway 5. The protein sequence contains a mito-
chondrial targeting signal peptide of 54 amino acids for mitochondrial import which is cleaved of dur-
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ing transport into the inner mitochondrial membrane. The mature protein has a weight of 42 kDa and 
is supposed to be active as a homodimer 55;56. Mature FECH possesses a [2Fe-2S] iron-sulfur cluster, 
which is not present in prokaryotic FECH proteins but is necessary for enzymatic activity in humans 
(Figure 1) 57-59. Taketani (2000) and Crooks (2009) suggested a stabilizing function 60;61.  
At the transcriptional level, FECH is regulated by a 150 bp minimal promoter region containing bind-
ing sites for the ubiquitous Sp1 family transcription factors and the erythroid-specific trans-acting fac-
tors NF-E2 and GATA1 62. During erythropoiesis an additional promoter region of approximately 4 kb 
is used to up-regulate FECH mRNA synthesis 63;64.  
Mutations in the FECH gene are associated with erythropoietic protoporphyria (EPP; OMIM 17700), 
characterized biochemically by the accumulation of the last precursor of heme biosynthesis, 
protoporphyrin IX 65 and clinically by cutaneous phototoxicity and in some cases, microcytic hypo-
chromic anemia 66-69. From mouse models of EPP, it is known that the genetic background influences 
disease severity 70 which indicates modifying genes also play a role in the human phenotype. Knock-
out of several genes has been shown to interfere with heme biosynthesis and inducing PPIX accumula-
tion. However these mice did show other symptoms in addition to that of EPP. For example, Irp 2-/- 
mice accumulate PPIX and Zn-PPIX, have reduced TfR levels and normal transferrin saturation. They 
show a microcytic, hypochromic anemia, absence of bone marrow iron stores, and develop neuro-
degeneration due to axonal degradation 51. Recently, the disruption of the gene coding for iron trans-
porter protein Abcb10 in mice was shown to cause anemia with accumulations of both iron and PPIX 
71.  
Wang et al. (2011)72 showed that in human EPP and XLDPP patients, an aberrant mitoferrin-1 
(SLC25A37) mRNA is detectable, that possesses a premature 477 bp segment of intron 2 with a ter-
mination codon and is therefore degraded by nonsense mediated decay (NMD); a surveillance mecha-
nism to remove faulty mRNA 73. Furthermore, Troadec et al. (2011) showed that mice with targeted 
disruption of mitoferrin-1 gene showed anemia and increased hematopoiesis74. When the mitoferrin-1 
gene was disrupted in hepatocytes, PPIX accumulated when the mice were fed aminolevulinic acid. 
Another mouse model with deletion of the ATP-binding cassette drug transporter breast cancer re-
sistance protein 1/ Abcg2 (Bcrp/Abcg2) showed elevated levels of PPIX in erythrocytes, indicating 
that PPIX is a target of Abcg2 and that this transporter may modify disease severity 75;76. Han et al. 
(2005) reported that heme-regulated eIF2alpha inhibitor (Hri) knockout mice accumulate PPIX in 
erythrocytes and that disease severity is modified by this protein 77.  
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Figure 1 
Structure of human ferrochelatase (FECH), stereo view on (a) symmetry axis and (b) active centre with PPIX 
bound. The iron sulphur cluster is depicted in violet and green. Image based on x-ray structures from Protein 
Data Base, 2 HRE (http://www.rcsb.org/pdb/explore.do?structureId=2hre). Description of structure by Medlock 
et al. (2007). The image was generated using YASARA View (www.yasara.org) by Thorsten Schweikardt, with 
kind permission.   
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2.4. Iron metabolism and erythroid heme biosynthesis 
Iron is an integral part of heme and necessary for life, but toxic when present in excess 78. The human 
body contains around 3 - 5 g iron of which 1 - 3 mg has to be substituted daily. Around 70 % of this 
iron is bound in hemoglobin in the hematopoietic system and 30 % is used in hemoproteins, iron-
sulfur cluster containing proteins or stored inside ferritin complexes in the liver, bone marrow and 
spleen. During uptake from food source in the intestine, ferric iron is reduced to ferrous iron by mem-
brane bound ferrireductases located at the enterocytes and absorbed by divalent metal transporter 1 
(DMT1 / SLC11A2 / NRAMP2). Iron is then transported through the cell lumen by an unknown 
mechanism. It enters the body through ferroportin (SLC40A1), the only known cellular iron exporter. 
In order to be exported and bound by the iron transporter protein transferrin, iron has to be oxidized to 
ferric iron by the membrane bound copper dependent oxidase hephaestin. In the circulation, two iron 
ions are bound and carried by transferrin which binds to transferrin receptor 1 (TFRC / TfR1) on the 
surface of iron utilizing cells.  For cellular iron uptake, the transferrin – transferrin receptor complex is 
internalized in clathrin-coated vesicle which undergo a pH change (acidification) inducing the release 
of iron from transferrin In order to be exported by DMT1 into the cytosol, the ferric iron has to be re-
duced by the metalloreductase STEAP3. Iron is then transported by an unknown mechanism either to 
the mitochondrium or to the sites of iron-sulfur cluster biogenesis. Since no physiological mechanism 
to excrete iron exists in the human body, its uptake and metabolism are tightly regulated 7.  The most 
important regulation of iron homoeostasis is exerted by the peptide hormone hepcidin which is synthe-
sized in the liver. Hepcidin production is enhanced in iron saturated conditions. It binds to ferroportin 
and induces its degradation, preventing iron uptake by inhibiting it’s release from the enterocytes. Af-
ter approximately three days, the enterocytes are replaced and iron is released from the cells. Enhanced 
hepcidin levels also prevent iron to be released from body iron stores, reducing the iron contend in cir-
culation 7; 81; 181. Fine tuning of the iron metabolism of internalized iron is mainly achieved by the iron-
responsive element (IRE) / iron regulatory proteins (IRP) system, which links heme biosynthesis and 
iron availability79;80. The untranslated regions (UTR) of the mRNAs of ALAS2 and of a subset of 
genes involved in iron uptake, transport and storage contain stem loop structures called iron-
responsive elements (IRE) that act as binding sites for the iron regulatory protein 1 and 2 (IRP 1 and 
IRP 2) 81. IRP 1 possesses a [4Fe-4S] iron-sulfur cluster and if iron is present, it acts as a cytosolic 
aconitase that converts citrate to isocitrate 46. IRP 2 is degraded under iron saturated conditions. In 
contrast, a low cellular iron-content leads to the binding of IRP 1 and IRP 2 to IRE. In mRNAs with an 
IRE located at the 3`UTR, binding of IRP 1 and IRP 2 stabilizes the mRNA by protecting it against 
endonuclease cleavage and therefore enhances the expression of the protein. When localized in the 
5`UTR, binding of IRP 1 and IRP 2 to the IRE leads to a block of translation and subsequently lower 
expression. Genes with IRE at 3`UTRs are transferrin receptor-1 (TfR1) which is the main receptor for 
iron uptake into the cell, and the divalent metal transporter 1 (DTM1) which is responsible for intesti-
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nal iron and other divalent metals absorption as well as for transport within cells in the body. 5`UTR 
IREs are found in mRNAs of ALAS2, of ferritin heavy chain (FTH1) and ferritin light chain (FTL), 
both of which are involved in iron storage 82;83 and of ferroportin (SLC40A1), the only identified cellu-
lar iron exporter 84. Overall, low cellular iron conditions increase the expression of proteins that are 
involved in iron uptake and mobilization and decrease proteins that are involved in iron storage and 
consumption. Additional mRNAs containing IREs have been identified, however their in vivo function 
has to be demonstrated and / or the genes have unknown function in regard of iron metabolism 85. 
Mammalian FECH mRNA does not possess an IRE, however the mature enzyme contains a [2Fe-2S] 
iron-sulfur cluster which is necessary for enzymatic activity in humans 57;58. Taketani (2000) and 
Crooks (2010) noted a connection between FECH expression and iron availability, possibly mediated 
by the stability of this cluster 60;61.   
 
2.5. Splicing in heme biosynthesis 
Several of the heme biosynthetic genes are alternatively spliced to give rise to erythroid specific and 
housekeeping mRNAs. Additionally, alternative splice variants are found with regulatory or unknown 
function, and a number of diseases-causing splice mutations are described for each gene. In general, 
protein coding genes are transcribed from DNA into one long, uninterrupted RNA molecule, the pre-
cursor-messenger RNA (pre-mRNA). However, most of the sequences transcribed to pre-mRNA do 
not contain information which is used for protein translation. Splicing is a highly complex, regulated 
process of joining protein coding sequence elements (exons) of the pre-mRNA together and excluding 
sequences without protein coding information (introns) to obtain the mature mRNA used for protein 
translation. The complex splice reaction is extensively reviewed by Maniatis and Tasic (2002) 86. In 
short, a stepwise self-assembling multi-protein complex called spliceosome recognizes sequence ele-
ments on the pre-mRNA and connects the end of the preceding exon with the beginning of the follow-
ing exon by a two-step trans-esterification reaction. The splice reaction involves a nucleophilic attack 
of a specific adenine (A) nucleotide, the branch point, towards the 5`end of the intron, leading to the 
formation of a lariat shaped intermediate intron structure. In a second step, by connecting both exons, 
this lariat is removed. The most important spliceosomal proteins are the U1, U2, U4, U5 and U6 small 
nuclear ribonucleic particles (snRNP) which contain short RNA sequences as catalytic elements or for 
recognition of their targets. Necessary sequence elements for the splicing of exons are the 3`acceptor 
site consisting of an AG dinucleotide at the end of each intron, preceded by a polypyrimidine rich se-
quence (py-tract), a branch point A nucleotide surrounded by a conserved sequence 20-30 bp upstream 
of an exon and a 5` donor site at the beginning of the intron often consisting of a GU dinucleotide. Be-
sides those core sequence elements, further binding sites for splice regulatory proteins exist which are 
crucial for the regulation of splicing. The most important additional sequence elements are binding 
sites for exonic and intronic splice enhancer or silencer proteins which exhibit a synergetic effect by 
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determining inclusion or exclusion of exons or introns. Alternative splicing of one or more exons is 
found in over 95% of the roughly 24.000 genes contained in the human genome 87 and accounts for the 
large variety of proteins found among different cell types, developmental stages or in response to an 
external signal.  
In heme biosynthesis, the genes coding for ALAD, PBGD and UROS contain both erythroid and 
housekeeping promoters and are alternatively spliced according to their expression in the respective 
tissue. In erythroid tissue, ALAD mRNA contains the exon 1B instead of 1A 88. The erythroid splice 
variant of PBGD mRNA contains exon 2 but not exon 1, as opposed to exon 1 that is present in the 
housekeeping variant 89-91. In the erythroid mRNA of UROS, exon 2A is included instead of exon 2B 
92. In addition to tissue specific splicing, alternative splicing giving rise to mRNA variants with known 
or unknown function or deleterious effects are found in other heme biosynthetic mRNAs. In ALAS1, 
two alternative splice forms exists, a more abundant one in which an alternative exon 1A is joined to 
exon 2 which shows sensitivity to heme mediated degradation, and a less abundant mRNA form con-
taining exon 1B which renders the protein insensitive to inhibition by heme 26-28. In ALAS2, a major 
splice isoform lacking exon 4 has been identified, accounting for 35-45% of the total transcripts 93. 
This splice variant shows a slightly reduced activity; however it possesses the transport signal for mi-
tochondrial import and therefore most likely contributes to the overall ALAS2 activity. In FECH, two 
major mRNA variants with unknown function exist with a length of 2.5 and 1.6 kb 94 which differ in 
their polyadenylation sites. For all heme biosynthetic genes, splice mechanism-affecting and disease-
causing mutations have been found. Of special interest is the single nucleotide polymorphism IVS3-
48C in the FECH gene 95 which together with a mutation in trans, is disease-causing and is found in 
over 97 % of overt EPP cases (Chapter IV).  
Divalent metal transporter 1 (DMT1, also called natural resistance-associated macrophage protein 2, 
NRAMP 2 or divalent cation transporter 1, DCT1) is a transmembrane transporter for divalent metals 
and necessary for intestinal iron absorption and iron transport among different cell types. Its mRNA 
harbors an IRE in the 3`UTR which is bound by IRP when iron is scarce. The binding stabilizes the 
mRNA by protecting it against endonuclease degradation and leads to higher expression of the protein 
and therefore enables enhanced iron uptake 96. Two major splice forms of DMT1 exist, one having the 
3`UTR IRE, and a second splice form lacking IRE. DMT1 is ubiquitously expressed and the two 
splice forms show tissue-specific distribution 97. Hubert and Hentze (2002) later identified an alterna-
tive exon 1B, the inclusion or exclusion of which leads to two additional mRNA splice variants 98. In-
clusion of exon 1B encodes an alternative in frame start codon and leads to a 5` prolonged protein with 
likely regulatory functions in iron metabolism.  
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3. Porphyrias 
 
Mutations in each gene of the heme biosynthetic enzymes lead to the accumulation of a subset of 
heme precursors and cause one specific form of genetic diseases named porphyria (Figure 2) 3;99. Ex-
ceptions are the housekeeping ALAS1, in which no disease-causing mutations are described, possibly 
because loss-of-functions of this enzyme are not compatible with eukaryotic life. In ALAS2, loss-of-
function mutations lead to X-linked sideroblastic anemia (XLSA; OMIM 300751) due to the inability 
to synthesize sufficient quantities of aminolevulinic acid (ALA) for heme synthesis. Based on their 
major side of excessive synthesis and accumulation of heme precursors, porphyrias can be grouped in-
to hepatic and erythropoietic forms. However, because of different management schemes, clinicians 
might prefer a classification into acute and non-acute forms (Figure 3) 100. Acute porphyrias are char-
acterized by potentially life-threatening acute neurovisceral attacks and extreme abdominal pain with-
out morphological anomalies of the tissue. Additional symptoms occur like nausea, headache, pain in 
the back and extremities, muscle weakness, vomiting, sweating, dysuria, constipation, tachycardia, 
hypertension and psychosis. The attacks are triggered by certain “unsafe” drugs which are metabolized 
by P450 cytochromes in the liver, by alcohol, hormones, stress and fasting 30. During acute attacks, 
high amounts of ALA and porphobilinogen (PBG) are excreted in the urine which is the most useful 
diagnostic marker of a symptomatic acute porphyria. Four acute porphyrias caused by mutations in 
heme biosynthetic genes exist: Acute intermittent porphyria (AIP) with a dominant mutation in the 
HMBS gene, variegate porphyria (VP) with a dominant mutation in the gene coding for the enzyme 
PPOX, hereditary coproporphyria (HCP) with a dominant mutation in the gene for CPOX and the ex-
tremely rare recessive delta-aminolevulinate dehydratase deficiency porphyria (ADP), in which ALA 
but not PBG is excreted. Besides the acute attacks, PV and HCP show sunlight sensitivity in form of 
bulbous lesions and scarring. Non-acute porphyrias are characterized by sun and light sensitivity with-
out abdominal pain. Porphyria cutanea tarda (PCT) is a hepatic, non-acute porphyria and shows bulb-
ous lesions and skin fragility and the diagnostic relevant accumulation of isocoproporphyrin in the 
stool. The hereditary form which occurs in roughly 30% of the PCT patients is caused by heterozy-
gous mutations in the gene for UROD. For a symptomatic manifestation, usually additional triggers, 
like iron accumulation in the liver due to an underlying hemochromatosis, alcohol abuse or environ-
mental factors are required. Besides the genetic form, sporadic PCT may occur, triggered by environ-
mental factors and genetic predisposition but with a normal UROD gene. Erythropoietic porphyrias are 
characterized by phototoxic reactions after sun and artificial light exposure associated with extreme 
pain and bulbous lesions. Congenital erythropoietic porphyria (CEP) is caused by recessive mutations 
in the UROS gene or its promoter region which cause uroporphyrin I and coproporphyrin I to accumu-
late in urine, blood and coproporphyrin I in the stool. In this disease light exposure leads besides ex-
treme pain, to severe skin injuries and to the loss of tissue and digits due to secondary infections. Due  
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Figure 2 
Heme biosynthetic enzymes, substrates and products and associated porphyrias. Mutations in each gene of the 
heme biosynthetic enzymes lead to the accumulation of a subset of heme precursors and cause one specific form 
of genetic diseases named porphyria. Exceptions are the housekeeping ALAS1, in which no disease-causing mu-
tations are described, possibly because loss-of-functions of this enzyme are not compatible with eukaryotic life. 
Heme biosynthetic enzymes: ALAS1 5-aminolevulinic acid synthase 1, ALAS2 5-aminolevulinic acid synthase 
2, ALAD Delta-aminolevulinate dehydratase, HMBS Hydroxymethylbilane synthase, UROS Uroporphyrinogen 
III synthase, UROD Uroporphyrinogen III decarboxylase, CPOX Coproporphyrinogen oxidase, PPOX Protopor-
phyrinogen oxidase, FECH Ferrochelatase. Substrates and products: ALA 5-aminolevulinic acid, PBG Porphobi-
linogen, HMB Hydroxymethylbilane, PPIX, Uro`gen III Uroporphyrinogen III, Copro`gen III Coproporphyrino-
gen IIII, Proto`gen Protoporphyrinogen, Protoporphyrin IX Porphyrias: XLDPP X-linked dominant 
protoporphyria, XLSA X-linked sideroblastic anemia, ADP Delta-aminolevulinate dehydratase deficiency por-
phyria, AIP Acute intermittent porphyria, CEP Congenital erythropoietic porphyria, PCT Porphyria cutanea 
tarda HCP Hereditary coproporphyria, VP Variegate porphyria, EPP Erythropoietic protoporphyria  
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to deposition of porphyrins, teeth may acquire a reddish coloration. Newborns with CEP can be identi-
fied by brownish-red urine, they often show jaundice and must not be treated by visible blue light irra-
diation to destroy bilirubin which in CEP causes severe burns. X-linked dominant protoporphyria 
(XLDPP) and erythropoietic protoporphyria (EPP) accumulate free PPIX in their erythrocytes and 
show an indistinguishable clinical presentation with painful phototoxic reactions after light exposure, 
usually without acute visible changes of affected skin areas. After prolonged light exposure time red-
dening, burns and persistent swelling of the skin may occur. XLDPP is caused by gain-of-function 
mutations in the first and rate limiting enzyme, ALAS2, whereas EPP is caused by mutations in FECH, 
the last enzyme of the pathway 52;101. 
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Figure 3 
Classification of porphyrias according to their symptoms and main site of heme precursor overproduction 
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4. Erythropoietic Protoporphyria  
 
4.1. Inheritance of EPP  
 
4.1.1. Mutations of FECH 
The ferrochelatase (FECH) gene has a size of about 45 kb, is located on chromosome 18q21.3 and 
contains 11 exons 102. At present, 189 loss-of-function mutations are described in the human gene mu-
tation database (HGMD), including missense and nonsense, splicing and regulation mutations, small 
deletions, insertions and indels, complex rearrangements and gross deletions affecting e.g. the promot-
er region or the entire gene.  
Only a few families with an autosomal recessive inheritance of EPP have been reported 103-109. The 
usual inheritance of EPP is however not dominant, but shows a more complex pattern 110, since not all 
FECH mutation carriers of a family develop symptoms. The inheritance of EPP is therefore described 
as autosomal dominant with incomplete penetrance 3 or by some authors as pseudodominant 111. Re-
cently it could be revealed, that the overt disease is dependent on the co-inheritance of a low expres-
sion allele in trans to a loss-of-function mutation of FECH. Rarely, de novo mutations are described 
and late onset cases connected to myeloproliferative disorders with somatic FECH mutations are ob-
served 112-118. 
  
4.1.2. Low expression allele  
In a thorough study by Went and Klasen (1984) including 200 patients from 91 Dutch families with 
EPP, they put forward the hypothesis of a 3-allele system of inheritance119. Gouya et al. (1996) identi-
fied a decrease in FECH activity co-inherited with an overt disease, strengthening the evidence of a 
low expression allele compatible with the 3-allele hypothesis120. Henrikson et al. (1996) and Schnei-
der-Yin et al. (2000) investigated the haplotype of the possible low expression allele and sequenced 
polymorphisms with strong linkage disequilibrium of the FECH gene 121;122. They identified the poly-
morphisms -251G located in the promoter region and IVS1-23T to be associated with the low expres-
sion allele, whereas -251A/IVS1-23C to be present in the control group and the allele carrying the 
FECH mutation. Gouya et al. (2002) could show that the common single nucleotide polymorphism 
(SNP) of FECH intron 3 IVS3-48C/T co-segregates with the low expression allele 95. In a minigene 
assay, they revealed that the SNP influences splicing of FECH (Figure 4): Intron 3 of the FECH pre-
mRNA can be either spliced correctly or alternatively at the aberrant splice acceptor site IVS3-63, lo-
cated 63 bp upstream from the correct splice site. The aberrant splicing results in a mature mRNA 
which contains additional 63 bp of intronic sequence. Due to the presence of a premature termination 
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codon (PTC) within this insertion, the aberrant splice product is subjected to nonsense mediated decay 
(NMD) and does not serve as a template for protein synthesis. In the mini-gene assay, Gouya et al. 
(2002) found that IVS3-48C/T determines the relative amount of normal and aberrant splice products 
95. If a T is present at the −48 position (IVS3-48T), only 10 to 20 % of the FECH pre-mRNA is aber-
rantly spliced. In an IVS3-48C genotype, however, the amount of aberrant splice product is increased 
to 30–40% of the total transcripts. The IVS3-48C SNP carrying allele is therefore denominated as 
“low expression allele”.  
 
 
 
Figure 4  
FECH intron 3 low expression due to partial aberrant splicing (modified from Gouya et al., 2002). Aberrant 
splicing causes a 63bp inclusion of intronic sequence, which carries a premature stop codon leading to degrada-
tion of the aberrant mRNA by nonsense mediated decay. Aberrant splicing is enhanced by the SNP IVS3-48C.  
 
 
Although reducing the amount of FECH produced, the IVS3-48C allele does not lead to an EPP phe-
notype – even in homozygous individuals (Figure 5). Only when the low expression allele is inherited 
in trans to a FECH loss-of-function mutation carrying allele and thus reducing the overall activity of 
FECH enzyme under a certain threshold level, the phenotype of EPP develops. Carriers of one FECH 
mutation are asymptomatic, whereas zygotes with a double null allele mutation do not develop, since a 
complete block of heme biosynthesis is not compatible with eukaryotic life. 
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Figure 5 
Inheritance of erythropoietic protoporphyria (EPP): The inheritance is described as autosomal dominant with in-
complete penetrance. Individuals with one FECH loss-of-function mutation (M) in trans to the frequent allele 
FECH IVS3-48T (T) are asymptomatic carriers of the mutation. When the low expression allele FECH IVS3-
48C (C) is inherited in trans to a FECH mutation carrying allele (M), it reduces the overall activity of FECH en-
zyme under a certain threshold level and the phenotype of EPP develops. The low expression allele (C) does not 
lead to an EPP phenotype, even in homozygous individuals (C/C). Zygotes with two loss-of-function mutation of 
FECH do not develop, since a complete block of heme biosynthesis is not compatible with eukaryotic life. Only 
a few recessive cases are described. 
 
 
4.1.3. Prevalence of the low expression allele and epidemiology  
The prevalence of EPP is dependent on the frequency of IVS3-48C in a population. The distribution of 
IVS3-48C/T differs among populations which suggest a positive selection pressure for this SNP in 
some population 123. In the European population, IVS3-48T is the more frequent genotype whereas 7% 
to 13% of the population carries the IVS3-48C genotype 124-127. The highest frequency of IVS3-48C is 
found in Asia, with Japan having 43% of its population carrying the SNP. In the French African im-
migrant populations, between <1% (West African origin) and 2.7 % (North African origin) of the pop-
ulation carry the low expression allele and accordingly only one EPP case has been reported in a man 
of black African origin 123;128. By haplotype analysis, the first occurrence of the mutation leading to the 
low expression allele was estimated to date back 60.000 years ago 123. The prevalence of EPP is esti-
mated to be 1:58.000 in Slovenia 129;130, 1:75.000 in the Netherlands 119, 1:79.000 in Northern Ireland 
131, 1:143.000 in the UK 132, 1:152.000 in South Africa 133, 1:155’000 in Switzerland67 and 1:180.000 
in Sweden 69. However, as the disease is often underdiagnosed for different reasons, the true preva-
lence of EPP is expected to be higher in many countries 69;99.  
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4.2. Clinical features  
 
4.2.1. Photosensitivity 
During development in the bone marrow, erythrocytes of EPP patients accumulate large amounts of 
free protoporphyrin (PPIX) which leaks into the blood during circulation where it attaches to the 
membranes of endothelial cells lining the blood vessels 134-136. Due to its ability to absorb visible light 
from sunlight and artificial light sources, PPIX is responsible for the main clinical symptom of EPP, 
extremely painful cutaneous photosensitivity 3. The symptoms are caused by sunlight and artificial 
light sources like intense halogen light bulbs and surgery light 137-139. The phototoxic reactions can 
trigger a cascade of symptoms, starting from discomfort to severe pain up to second degree burns 
which can be fatal in case of a surgery without appropriate light protection 140-142. Symptoms usually 
start within minutes after contact of uncovered skin and tissue to light and comprise of a prickling, 
stinging and itching sensation. Upon prolonged exposure times to light, a burning feeling and severe to 
unbearable neuropathic pain develops 67;132. Although clearly caused by light, EPP related symptoms 
are enhanced by different environmental conditions such as, cold wind, humidity and air temperature, 
time of the day and physical contact – an effect not understood at the moment but well documented in 
the literature 69;132;143;144. Typically, no acute visible changes are observed on the affected skin areas, 
only occasionally immediate reddening of the skin, blisters or bulbous lesions may develop in some 
individuals. After extreme irradiation events, with a delay of hours swelling, reddening and sunburn 
resembling signs may develop in some patients (Figure 6), whereas in others no visible changes are 
seen despite excruciating pain 122;145;146.  Severe pain can persist several days up to two weeks. Addi-
tionally, a painful sensitivity to even weak light sources, heat, cold, wind, body heat and physical con-
tact can persist which typically makes sleep impossible for several nights. Once a painful irradiation 
event happened, the onset of symptom during a subsequent sun exposure starts earlier, an observation 
described as “priming effect” 132;147. The individual sensitivity to the sun and artificial light correlates 
with PPIX values, varies among patients and is influenced by many factors: The amount of PPIX dif-
fers strongly among patients with a significantly higher mean value in male patients 69;132 and the 
amount of PPIX within one patient may vary, influenced by factors like season 65 and liver health 148. 
One case of increased light sensitivity and elevated PPIX levels was described in Grave’s disease hy-
perthyroidism which improved after treatment 149. An improvement of symptoms is also frequently ob-
served in pregnancy 69;150-153. Permanent visible changes of the skin comprise of a slight lichenification  
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Figure 6 
Visible symptoms after prolonged sun exposure in patients with erythropoietic protoporphyria (EPP). a) & b) 
Swellings in the face the day after sun exposure. c) habitus of an affected child during acute symptoms. d) severe 
erythema on the hand with sparing of the areas protected by rings the day after sun exposure. e) burns, erythema 
and scarring of the face several days after sun exposure. f) abatement of severe burns and swellings one week af-
ter last sun exposure, damage of the skin due to secondary infections related to scratching because of itching sen-
sation and to cooling with water and subsequent dry skin. Photos by Arun Barman (a-c), Selbsthilfe EPP e.V. 
(d), Swiss society for porphyria (e), and Kinderklinik Mannheim (f), with kind permission.   
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above the basal knuckles. In a minority of patients hyperkeratotic lesions on the face occur, especially 
on the nose, and deep wrinkles may develop around the mouth and eyes 122;132. 
The phototoxic reaction is caused by the physical properties of PPIX which is a planar, heterocyclic 
and highly conjugated circular molecule (Figure 7). Isolated PPIX has an absorbance maximum at 
405-410 nm in the visible blue range (Soret band) and minor absorption peaks at wavelengths between 
500 nm and 650 nm (Q-bands). Additional minor absorption bands are present in the near UV-A and 
the IR spectrum 154. As red light penetrates the skin deeper than blue light and might therefore particu-
larly reach the capillaries in the dermis, it is not conclusively clarified which wavelength is the main 
trigger for the symptoms in EPP patients 155;156. In acidic solution PPIX can emit the absorbed energy 
as fluorescence when excited with a blue light LED (Figure 7). In red blood cells of EPP patients 
when excited with wavelengths around 410 nm, a red fluorescence can be seen under a fluorescence 
microscope 157;158. In tissues, two types of photoreactions with the surrounding cellular structures are 
assumed. After absorption of the energy of photons with an adequate energy contends, PPIX is trans-
formed from its ground state to a short lived excited singlet state and then to an exited triplet state. The 
energy of this triplet state can be transferred directly to surrounding cell structures (photoreaction type 
I): An electron or proton is transferred most likely to the lipids of the cell membrane and/or peptides 
which turn into radicals. By interaction with cellular oxygen, reactive oxygen species (ROS) are pro-
duced. Alternatively, the energy of the excited triplet state can be directly transferred from PPIX to 
oxygen (photoreaction type II), whereby exited singlet oxygen is produced 159. Singlet oxygen is fur-
ther converted into ROS such as O2•, H2O2 and •OH which damage lipids and proteins of the cell. 
Considering the amount of PPIX present under physiological conditions in cells, type II is assumed to 
be the most prevalent type of photoreaction occurring in EPP 160.   
 
 
Figure 7 
a) Protoporphyrin IX (PPIX) is a planar, heterocyclic and highly conjugated circular molecule. Wikicommons li-
cence, author: Jü. b) Fluorescenece of protoporphyrin IX (PPIX) in 1.5 M HCl upon excitation with visible blue 
light (LED), image by the author. 
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4.2.2. Palmar keratoderma in homoallelic recessive patient 
A special phenotypic feature found exclusively in homoallelic recessive patient is palmar keratoderma 
108;109;161;162. The reasons for this additional clinical presentation have to be elucidated.  
 
4.2.3. Vitamin D and bone density  
Because of the avoidance of sunlight exposure, less vitamin D precursor is converted into its biologi-
cal active 25-hydroxyvitamin D form in the skin of EPP sufferers. Vitamin D deficiency is inversely 
correlated to the amount of PPIX, severity of symptoms and time to onset of symptoms 163;164. Con-
comitantly, one study by Allo et al. (2013) showed an overall low to insufficient bone mineral density 
in EPP patients165.  
 
4.2.4. Cholestatic liver disease and gallstones 
Due to its hydrophobic character, PPIX is cleared from the body only through the liver, where it is se-
creted via the bile. In the bile, gallstones composed of PPIX might form even in young age 145;166. The 
excess amount of PPIX exerts damage on the liver cells, as concluded by permanently increased liver 
transaminases and histological abnormalities in the liver tissue observed in most EPP patients. In 5-10 
% of patients, sudden rapidly progressing liver damage and subsequently liver failure occurs. Triggers 
for liver failure in EPP can be viral infections of the liver or sudden massive damage such as excessive 
alcohol consumption 167; however the exact aetiology is not understood at the moment and might con-
tain a component of genetic predisposition. Brown discoloration of the tissue and maltese-cross 
formed PPIX crystals are found in cells of affected livers. In severe liver involvement transplantation 
of a donor organ is necessary, in some cases liver and bone marrow transplants were used to protect 
the donor organ from further damage by the newly formed PPIX 141;148;168-170.  
 
4.2.5. Iron metabolism  
20-60% of EPP patients show low serum iron concentration and hematologic abnormalities which re-
semble those of iron deficiency i.e., low serum concentrations of iron, decreased transferrin saturation 
and abnormal hematologic indices including low hemoglobin, hematocrit, MCV and MCH and micro-
cytic and hypochromic anemia. Also iron storage can be decreased as assessed by low serum ferritin 
66-68;171. However, iron supplementation was found to be beneficial in some cases only while be coun-
terproductive in terms of worsening the skin symptoms in others – a paradox not explained so far 172-
174, own observation. In an animal model of EPP, a disturbance in iron metabolism rather than a defi-
ciency of iron was observed 175. In humans, no increase in soluble transferrin receptor was found in a 
cohort of EPP patients 68. Soluble transferrin receptor is an iron receptor which is present on the sur-
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face of developing erythrocytes. It is shed from the surface of the cells during development of the 
erythrocyte and therefore can be detected in serum. Iron deficiency leads to an increased expression of 
transferrin receptors which enhances the amount of soluble transferrin receptor detectable in the serum 
176. Delaby therefore concluded that iron is not the limiting factor of erythropoiesis in EPP.  
 
4.2.6. Delay of diagnosis and psychosocial impact 
As a hereditary disease, EPP related symptoms usually start in early childhood. The extremely painful 
events experienced by the patients together with the prompt appearance of it after short sun exposure 
times leads to an understanding of the cause – consequence relation by the sufferers already at young 
age. Patients therefore develop strategies to minimize sun exposure times from early childhood on. 
However, avoiding sunlight includes peculiar behavior e.g. wearing protective long cloth during sunny 
days or having to change to the shadow side of the street. Once symptoms started, the patient may 
show unusual measures in order to reduce the pain, e.g. cooling the affected areas of the skin with wet 
cloth. This behavioral adaption can isolate patients from their peers 177. A major complicating difficul-
ty is the absence of immediate visible changes of the skin despite severe pain which leads to the un-
derestimation of the severity of the symptoms by the social environment and physicians 145;146. Due to 
the absence of objective clinical signs, especially young patients often face allegations of being ma-
ligners or hyperactive. Therefore, in the attempt to be accepted as a normal member of society and 
their social groups, patients try not to openly show their discomfort. As a consequence, dissimulation 
becomes a deep rooted behavioral adaption in the majority of EPP patients which may lead to the un-
derestimation of the severity of the pain experienced. However, if visible signs occur, they are often 
mislabeled as “sun allergy”, although not comprising a valid diagnosis. As EPP is a rare disorder, most 
physicians and dermatologists are not aware of its existence, however even in case of EPP is consid-
ered as differential diagnosis, many textbook descriptions of the disease are misleading or wrong. Fre-
quently, only UV radiation is mentioned as provoking phototoxic reactions, although evidence such as 
the use of visible light sources in photodynamic therapy with PPIX and the lack of efficacy of sun 
screens and other protection measures against UV radiation clearly demonstrate that protection against 
visible light is the most important measure in preventing EPP symptoms 178. In many textbooks, the 
description of EPP is confused with other forms of porphyria like CEP, e.g. mentioning of red teeth, 
and sometimes it is written that males only are affected by EPP. All the above mentioned reasons lead 
to the delay of diagnoses by decades, despite the childhood being the most difficult time in the life of 
EPP patients 69;122;179.  
However, even with a correct diagnosis, many patients complain about not being taken seriously by 
health care professionals, e.g. insufficient photo protection during surgeries or when treatment deci-
sions are taken without consulting the patients experience with their own disease like the administra-
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tion of intravenous iron after which many patients observed a worsening of their photosensitivity. In 
addition, the need to visit a specialist for the disease is often denied by the familial physician which 
leads to insufficient and wrong knowledge transfer to the patients with consequences like neglecting 
the monitoring of liver function and iron metabolism, missing of new treatment possibilities or wrong 
advice, e.g. the often mentioned wrong causality between sun exposure and liver damage. The man-
agement of patients with EPP by general physicians sometimes also leads to highly questionable out-
comes like the attempt of a physician to perform liver biopsy without any medical need in a newly di-
agnosed eight year old female EPP patient (Minder, personal communication). Patients therefore face 
unnecessary risks if not treated by specialists. Also, the mentioning of an assumed connection of 
porphyrias to the origin of the vampire myth is considered as inappropriate and insulting by many pa-
tients (own observation). Already proved wrongly, this hypothesis is still described in nearly every 
textbook for medical students 180;181. 
 
4.3. Treatment options 
  
4.3.1. Amelioration of acute phototoxic reactions 
Since analgetics are insufficient to relieve the pain caused by light in EPP 160, avoidance of further ex-
posure is the most important measure once acute phototoxic reactions developed. Temporal pain re-
lieve is achieved by cooling the affected skin areas with cold water, air-flow or by pressing the skin on 
cool surfaces. Cooling however only is effective for short time periods and does subsequently increase 
the sensitivity to heat. Treatment with moderate heat in form of e.g. warm water has been described by 
patients to improve the condition and shortens the time until pain resolves (own observation).  
 
4.3.2. Photoprotection 
Since in EPP visible light causes phototoxic reactions of exposed skin areas and tissue, UV protection 
measures are not sufficient to prevent symptoms – which can be depicted by the fact that EPP symp-
toms also start when the patients remain behind window glass which effectively filters most UV radia-
tion 178. Therefore, complete light avoidance would be the most effective prevention of symptoms such 
as physical barriers, like thick, dense cloth, shade providing items like huts, gloves or umbrellas or 
make-up preventing light penetration into the skin. However, such devices are only partly effective, 
i.e. because of hands and face are not completely covered. 
Different drugs to reduce phototoxic reactions have been tested since the 1970s. The carotenoids beta-
carotene and canthaxantin were believed to reduce oxidative stress in the skin as seen in plants by 
scavenging radical oxygen species (ROS). Canthaxantin was later found to induce crystal formation in 
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the eye when taken in high doses and was therefore withdrawn as treatment option for EPP 182. How-
ever, results with beta-carotene were unsatisfactory with regard to photo protection183. In addition, a 
recent study by Virtamo (2013) showed that high doses of beta-carotene as recommended for the 
treatment of EPP increase the risk for lung cancer, although in smokers only184. Other substances with 
antioxidative properties used in single studies on a limited number of participants were cysteine, N-
acetyl-cysteine (NAC) and vitamin C 185-187. UVB exposure was used to increase melanin density and 
dihydroxyacetone/ Lawson (henna) was employed for coloring the skin, both were approaches to in-
duce a physical barrier preventing light from penetrating the skin. However, in a systematic 
metastudy, Minder (2009) showed that none of the tested therapies did significantly protect against 
EPP related phototoxicity183. Importantly, this lack of efficacy is in concordance with self-reports of 
patients when asked outside of the study setups e.g. free from expectations of the respective PIs. Sole-
ly UVB-treatment did show a protective effect, however the increased risk for skin cancer by UV ex-
posure makes this option not applicable in young patients and for long term use in this lifelong condi-
tion 188;189. 
In 2006, a Swiss clinical phase II trial tested a new approach with the synthetic alpha-melanocyte-
stimulating hormone (α-MSH) analogue afamelanotide ([Nle4, D-Phe7]-α-MSH, SCENESSE®)190. 
Afamelanotide is a linear peptide of 13 amino acids in length which does not cross the blood-brain 
barrier. It binds to melanocortin-1-receptor (MC1R) on melanocytes of the skin and induces melanin 
synthesis and subsequently skin tanning by the same mechanism as the natural hormone. The amino 
acid sequence of afamelanotide is modified from the natural occurring sequence at position four, 
where methionine is exchanged by norleucine and at position seven, where an l-phenylanaline is re-
placed by d-phenylalanine. The modifications confer higher binding capacity to the receptor and a 
higher resistance to decay mechanisms. Since the half-life of α-MSH is in the range of minutes, the 
more stable and potent analogue afamelanotide is used in an implant formulation. Besides the tanning 
effect, α-MSH and afamelanotide have strong anti-inflammatory properties. Up to date, more than 350 
EPP patients worldwide were included in multicentre clinical phase III trials, all showing efficacy of 
the treatment which is well tolerated without major side effects. Afamelanotide (SCENESSE®, 
Clinuvel Pharmaceuticals Ltd.) has been submitted to the European Medicinal Agency (EMA) for 
marked authorization and has been assigned the orphan drug status. At present, it is available for the 
treatment of EPP patients in Italy and Switzerland under special legislation for severe and incapacitat-
ing orphan diseases without treatment options. 
 
4.3.3. Photoprotection during surgeries 
Intense artificial light sources like surgery lamps can cause severe to lethal injuries during surgical in-
tervention 191. Especially in liver involvement, higher PPIX concentrations are accumulated in the 
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body and exacerbate the phototoxicity. Protective yellow filters should be used during surgeries to 
prevent or limit phototoxic injuries 192.  
 
4.3.4. Vitamin D supplementation 
Serum vitamin 25(OH)D levels should be monitored and supplemented in case of a deficiency. Since a 
normal, well-balanced diet usually contains enough calcium and other trace elements, preferably vita-
min D supplementation without calcium should be used. Otherwise, addition of calcium without defi-
ciency may compete with the incorporation of phosphate which is necessary for the building of a 
healthy bone architecture 193. 
 
4.3.5. Transplantation in cholestatic liver disease 
Photoprotection does only symptomatically treat EPP and, since by such a treatment the amount of the 
liver toxic agent PPIX is not reduced, does not confer protection against liver injury. In case of liver 
involvement, a transplantation of a donor organ has to be conducted to stop the otherwise fatal pro-
gression of liver damage. A curative treatment for EPP can be achieved by transplanting the liver and 
bone marrow from a donor 194;195. The high risks associated with such a holistic intervention make it 
only applicable in severe and otherwise terminal liver failure caused by excess PPIX with the risk of 
damage to the donor liver caused by constantly high PPIX production during erythropoiesis 170;196. Ap-
proaches like red cell blood exchange were unsuccessfully used in an attempt to diminish liver damage 
by reducing the amount of PPIX present in the blood 197 and dialysis with albumin only showed mar-
ginal effects 198;199. Also treatment with oral cholestyramine which discontinues the enterohepatic cir-
culation of bile acids and is used in the attempt to increase bilary PPIX excretion, has been shown to 
be not effective in a small study with 3 patients with uncomplicated liver 200. One attempt to reduce 
liver damage by N-acetyl cysteine has to be investigated in a larger trial 201.  
 
4.3.6. Gene therapy 
A curative approach to treat EPP would be gene therapy, the correction of the mutated DNA of own 
body cells. Despite successful tests in a mouse model for EPP 202, the technique is not yet mature 
enough for human trials and connected to a number of concerns which have to be considered first. Re-
cently, splice modulating oligonucleotides have been described which target the low expression allele 
in EPP and correct aberrant splicing to form additional mRNA and subsequently FECH protein 203. 
However, a proof of concept in a humanized mouse model and a technique how to target 
erythropoietic precursors in the bone marrow in a sensitive developmental stage of porphyrin accumu-
lation will remain a challenge for this interesting therapeutic approach.  
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II. AIMS OF THE STUDIES:  
 
Erythropoietic protoporphyria (EPP) is associated with a change in serum iron parameters and a mi-
crocytic, hypochromic anemia both indicating iron deficiency. However, clinical experience showed 
that iron supplementation aggravated the symptoms of EPP, an up-to-now unexplained phenomenon.  
On the other hand, over 97% of EPP patients carry the splice modulating SNP IVS3-48C/T which en-
hances aberrant splicing of intron 3. Since iron, heme metabolism as well as splicing are highly regu-
lated processes, an assumed connection among them builds the working hypothesis of this thesis.  
All three studies selected for this thesis therefore focus on aspects of regulatory mechanisms and ex-
pression of genes related to EPP and heme synthesis, possibly influenced by iron availability. We spe-
cifically wanted to perform studies concerning the following issues:  
 
1. An in-depth characterization of FECH intron 3 to reveal whether additional sequence features 
exist that may be related to the disease causing splice defect 
2. Whether the alternative splicing of FECH intron 3 has a regulatory function, especially 
a. Whether any of the substrates or products of the FECH reaction iron, protoporphyrin 
IX, heme or zinc-protoporphyrin IX influence the splice side choice of FECH intron 3 
b. Which splice factors are involved in the alternative splicing and its supposed regula-
tion  
c. Whether the polymorphism FECH IVS3-48 which influences the ratio of the splice 
side choice also has an influence on the supposed regulatory process 
3. Possible reasons for the observed exacerbation of symptoms after iron supplementation, espe-
cially to test our hypothesis that ALAS2 is involved in the pathophysiology of EPP 
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III. RESULTS  
 
STUDY I 
 
Variations in the length of poly-C and poly-T tracts in intron 3 of the human ferrochelatase gene 
 
The third intron of human ferrochelatase (FECH) gene contains two homopolymeric tracts, a stretch of 
cytidines (poly-C) and thymidins (poly-T) which are located approximately 900 bp upstream from the 
known splice modulating SNP IVS3-48C/T. According to the NCBI database, the length of the tracts 
is 11 cytidines and 24 thymidins. Since we previously sequenced intron 3 of volunteers and found dif-
ferences to the reference sequence, we analyzed the length of those tracts in 23 healthy controls homo-
zygous for the T-variant of IVS3-48T/T, 14 healthy heterozygous controls (C/T), 7 unrelated EPP mu-
tation carriers (M/T; M stands for FECH mutation) and 10 unrelated EPP patients (M/C). The length 
of the poly-C tracts in the study cohort varied from 10 to 16, and that of the poly-T tracts from 22 to 
24. Statistical analysis showed, that the low-expressed FECH allele (IVS3-48C) is associated with 
longer poly-C tracts (poly-C12, -C13 and -C15) and poly-T22. In addition, the segregation of poly-C 
and poly-T tracts was studied in two Israeli EPP families. Instabilities, as seen by both insertion and 
deletion of one nucleotide between two generations, were observed in the poly-T tract. A possible 
function of the observed variations in the length of homopolymeric sequence in introns has to be elu-
cidated.  
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STUDY II 
 
Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-
oxoglutarate dependent dioxygenase Jmjd6 and U2AF65 
 
In Study II, we tested whether the FECH substrate iron or the products heme or zinc-protoporphyrin 
IX (Zn-PPIX) exhibits a modulating function on the splice side choice of FECH intron 3 in vitro. We 
used the erythroleukemic K562 and lymphoblastoid cell lines previously generated in our laboratory 
from healthy and EPP affected volunteers with different genotypes regarding the splice modulating 
SNP (IVS3-48T/T; C/C and M/C). While addition of iron, heme and Zn-PPIX had no influence on the 
splice ratio, treatment with chelators to reduce iron availability altered the choice of the splice site: de-
pletion of iron with the chelators deferoxamine (DFO) or 1,2-dimethyl-3-hydroxy-4-pyridone 
(deferiprone) resulted in a decrease of the correct spliced FECH mRNA and, concomitantly, an in-
crease of the aberrant splice product in the erythroleukemic K562 cell line. The amount of FECH pro-
tein was measured under normal conditions and under DFO treatment which was found to be de-
creased, too. The effects were shown to be prevented by neutralizing the chelator DFO with equimolar 
amounts of iron (ferric ammonium citrate, FAC) and were reversed upon treatment with iron 24 h after 
treatment with the chelator. Interestingly, the strongest effect was detected in the erythroleukemic 
K562 and lymphoblastoid cell lines both homozygous for IVS3-48T, where the aberrant splice product 
increased to 56% and 50% of total FECH mRNA, respectively. Iron deficiency had less effect on the 
FECH splice ratio in the investigated lymphoblastoid cell line homozygous for the SNP IVS3-48C and 
a cell line with the EPP-genotype (M/C).  
To elucidate the mechanism of the splice alteration modulated by iron availability, we tested whether 
the dioxygenase Jumonji domain-containing protein 6 (Jmjd6) is involved in the FECH splice reac-
tion: Jmjd6 is an iron (II) - and 2-oxoglutarate-dependent dioxygenase recently described to interact 
with the splice factor U2AF65 by lysyl-hydroxylation. U2AF (U2 snRNP auxiliary factor) is an essen-
tial splicing factor composed of two subunits. The large subunit of 65-kDa (U2AF65) binds to the 
polypyrimidine tract (PY-tract) upstream from the 3′ splice site and promotes U2 snRNP binding to 
the pre-mRNA. The small subunit U2AF35 is important for the splicing of introns that contain short or 
weak PY-tracts. However, the recognition of a weak 3′ binding site requires the interaction between 
the two subunits. The correct splice site of FECH intron 3 is indeed very weak and proceeded mostly 
by short sequences of 3 or less cytosines or thymines (Cs/Ts), whereas the aberrant splice acceptor site 
contains a strong polypyrimidine stretch of 15 Cs/Ts. By consecutively applying different inhibitors 
we were able to demonstrate an involvement of the splice factor U2AF65 and Jmjd6 in the splice site 
choice of FECH intron 3 by iron availability.  
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Inhibition of Jmjd6 activity can be achieved by iron deprivation with either iron chelators such as DFO 
or deferiprone, by competitive inhibition of iron binding with CoCl2, by competitive inhibition of 2-
oxoglutarate binding with DMOG, and by suppression of transcription with specific siRNA against 
Jmjd6. Inhibition of U2AF65 can be achieved by siRNA. Upon inhibition of either Jmjd6 or U2AF65, 
the splice ratio shifts toward the aberrant product, leading to fewer amounts of both FECH mRNA and 
protein.  
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STUDY III 
 
In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and 
erythrocytic protoporphyrin-concentration correlates with iron availability 
 
Patients with erythropoietic protoporphyria (EPP) often show signs of iron deficiency, in addition to 
the symptom of photosensitivity which is caused by the accumulation of the second substrate of this 
enzyme, protoporphyrin IX (PPIX). However, iron supplementation frequently leads to exacerbation 
of phototoxicity. By analyzing hematological laboratory data from three EPP patients over a prolonged 
time span, we found low hemoglobin (HGB) correlated with a reduced PPIX concentration in erythro-
cytes whereas higher amounts of HGB were associated with higher PPIX concentrations. To explain 
our finding, we performed further analyses among a cohort of EPP patients which revealed increases 
in the amount of both mRNA and protein of the erythroid-specific isoenzyme 5-aminolevulinic acid 
synthase (ALAS2) in peripheral blood samples. The amount of ALAS2 mRNA in EPP patients was 
determined to be 782.7 arbitrary units (a.u.; interquartile range: 329.0 – 948.7 a.u., n=15) and that of 
healthy controls 194.8 a.u. (90.9 - 360.0 a.u., n=20). ALAS2 protein in EPP patients was found to be 
two-fold increased compared to healthy subjects. To verify our finding, we performed in vitro experi-
ments to inhibit FECH with N-methyl protoporphyrin (NMPP), a known inhibitor of FECH activity, in 
the erythroleukemic K562 cell line and were able to measure a two-fold increase in ALAS2 mRNA 
subsequently. The results of this study brought new insights into the pathogenesis of EPP, i.e. the pri-
mary deficiency in FECH leads to a secondary increase in the expression of ALAS2 which is the first 
and rate-limiting enzyme in the erythroid heme biosynthetic pathway. A higher activity of ALAS2 
combined with a lower activity of FECH contributes to the accumulation of PPIX in EPP. The transla-
tion of ALAS2 is regulated by IRE-binding proteins (IRP) 1 and 2 which bind at an iron-responsive 
element (IRE) present in the 5`UTR region of ALAS2 mRNA which blocks translation if iron is 
scarce. The frequently observed iron deficiency among EPP patients could therefore act protective 
against an unlimited PPIX production by restricting ALAS2 over-expression. 
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IV. DISCUSSION  
 
In over 90% of EPP cases, the underlying genetic defect consists of the splice modulating SNP IVS3-
48C (low expression allele) in trans to a mutation of the FECH allele 95;107. The splicing reaction is 
complex and not entirely understood and is influenced by a plethora of sequence and protein factors. 
In Study I, we therefore investigated sequence features of FECH intron 3, a poly-C and a poly-T 
homopolymeric tract located approximately 900 bp upstream of the splice site. Stretches rich in T and 
C nucleotides (polypyrimidine tracts) are binding sites for splice factors when preceding splice accep-
tor sites, and deletions in homopolymeric poly-T tracts are reported to result in aberrant splicing in 
cancer related genes such as ATM and MRE 11 204;205. A poly (C)–binding protein 1 (PCBP1) exists 
which seem to function as a cytosolic iron chaperone. It binds ferritin and increases the amount of iron 
bound by ferritin when expressed in yeast cells. Disruption of PCBP1 expression in human cells leads 
to an increase in cytosolic iron and a decrease in ferritin iron 206. In general, homopolymeric tracts are 
significantly over-represented and more widely spread in the genome than simply by chance, indicat-
ing a function 207;208. In our study, we demonstrated an association of the low expression allele IVS3-
48C with longer poly-C tracts (poly-C12, -C13 and -C15) and poly-T22. In the poly-T tract, a differ-
ence of only one nucleotide between the two alleles has been observed in the study subjects. Addition-
ally, in segregation studies of two Israeli families, single nucleotide deletions and insertion in the poly-
T tract were observed. However, possible functions of the poly-C and poly-T tracts in the FECH gene 
remain to be studied. 
One of the hitherto not sufficiently understood phenomena of EPP is the adverse reaction on iron sup-
plementation in many individuals affected by EPP. Although 20-60% of EPP patients show low serum 
iron concentration and hematologic abnormalities which resemble those of iron deficiency, i.e. micro-
cytic and hypochromic anemia 66, iron supplementation was found to be beneficial in some cases only 
209;210, while to be counterproductive in terms of worsening the skin symptoms in others 172-174, own 
observation. Additionally, the fate of iron in the organism of an EPP patient is not understood at the 
moment 66;68. The biosynthesis of heme is tightly regulated since its intermediary porphyrins as well as 
the end product heme are toxic to the organism if present in excess (reviewed in references 3;6;211). A 
regulatory function of alternative splicing with a PTC, termed regulated unproductive splicing and 
translation (RUST), has been described in a number of genes 212. Our guess that iron itself or the prod-
ucts of FECH reaction, either PPIX or Zn-PPIX might negatively influence the splice site choice of 
FECH intron 3 was confirmed, but in a way not foreseen by us (Study II): The worsening of the 
symptoms under iron therapy would suggest, that iron or FECH reaction products in a kind of feed-
back inhibition negatively affect the FECH protein or its activity. However, we could not find an ef-
fect of enhanced cellular iron content, but found that the deficiency of iron causes the correctly spliced 
mRNA to decrease and the aberrantly spliced mRNA to increase. Concomitantly, the amount of FECH 
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protein decreased. A common splice factor, U2AF65, which is modified by the iron dependent 
dioxygenase Jmjd6 213 was studied in detail and could be identified as a link between iron metabolism 
and splicing of FECH. In iron deficiency, Jmjd6 activity is inhibited and less U2AF65 can be modified. 
Subsequently, the recognition of the correct splice site is no longer supported. The splice ratio shifts 
toward the aberrant product, leading to fewer amounts of both FECH mRNA and protein - which is 
reasonable since in the absence of substrate the enzyme is dispensable. 
Interestingly, the observed effect is strongest in the two cell lines without the low expression allele but 
the common genotype IVS3-48T/T. In cell lines bearing the low expression allele (IVS3-48C/C and 
M/C (EPP)), the baseline amount of aberrantly spliced FECH mRNA is higher. However, under iron 
depletion, the increase in aberrantly and decrease in correctly spliced FECH mRNA is less pro-
nounced. Assuming that the described effect of iron deprivation on splicing in the T/T genotype has a 
regulatory feature, the observed loss in sensitivity in the IVS3-48C background constitutes a loss of 
potential for regulation. Taking both together, the increase in aberrant splicing under baseline condi-
tion and the less pronounced increase in aberrant splicing compared to the T/T genotype under iron 
deprivation indicate that even if enough iron is available, the C/C genotype is less sensitive to iron de-
ficiency. 
Based on the clinical observation, that iron supplementation can lead to aggravation of EPP symptoms, 
we hypothesized in Study III that ALAS2 is involved in the etiology of EPP: ALAS2 is the first and 
rate-limiting enzyme of erythroid heme biosynthesis. The mRNA of ALAS2 harbors a structural ele-
ment, the iron response element (IRE), which upon binding of the iron response protein (IRP) prevents 
translation of the mRNA if iron is scarce - but enables protein synthesis if iron is available. Surprising-
ly, we found ALAS2 mRNA to be enhanced in peripheral blood samples of EPP patients compared to 
healthy controls. Since also ALAS2 protein was increased, the IRE-IRP system seems to only partially 
exert a block of ALAS2 translation in EPP. Therefore, one may speculate that an enhanced ALAS2 ac-
tivity contributes to the excess amount of PPIX accumulating in EPP. Furthermore, iron supplementa-
tion could lead to a de-repression of the IRE block which would further increase the amount of 
ALAS2 enzyme and explain the worsening of the EPP symptoms under iron therapy.  
Out of ethical considerations, no study to provoke an enhancement of PPIX due to higher amount of 
ALAS2 after iron supplementation can be conducted. However, we analyzed the data of three EPP pa-
tients from our clinic who received iron therapy because of low hemoglobin levels and pronounced 
anemia with fatigue and fainting. Two of the patients displayed markedly increased levels of soluble 
transferrin receptor which is seen as the most reliable marker for iron deficiency in EPP. Since both 
patients responded with an increase in hemoglobin after iron administration, we interpret hemoglobin 
as a measure for the amount of iron available for erythropoiesis. A positive correlation between the 
amount of hemoglobin and PPIX was found in all three patients, indicating that iron stimulates PPIX 
production. This observation is explicable by the interpretation that iron stimulates ALAS2 expression 
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which results in higher PPIX values. Therefore, possible benefits of an iron supplementation therapy 
in EPP patients should be carefully weighed against an increased PPIX burden, especially in regard of 
liver damage caused by increased PPIX blood concentrations.  
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V. CONCLUSION  
 
The presented studies show that  
 
1. The alternative splicing observed in FECH intron 3 (IVS3-48T) is a regulatory feature which 
links iron availability to amount of enzyme. This regulatory sequence element is conserved in 
primates, which adds evidence to the hypothesis that the splice alteration is part of a regulato-
ry mechanism described as Regulated Unproductive Splicing and Translation (RUST).  
 
2. The splice-modifying and disease-causing FECH SNP IVS3-48C exhibits a de-regulation in 
regard to the splice regulation in such that it displays higher levels of aberrant splicing under 
iron-saturated conditions and less inducibility of aberrant splicing in iron depletion compared 
to the IVS3-48T genotype. 
 
3. ALAS2, the first and rate limiting enzyme of erythroid heme biosynthesis, is enhanced in EPP 
at the mRNA and protein level. Although considered a monogenetic disease, the aetiology of 
EPP is therefore more complex and includes possible feedback regulation which might lead to 
new treatment options. 
 
4. Further evidence and a proposition for an underlying mechanism could be added to the obser-
vation, that iron therapy in EPP patients may be accompanied by adverse effects. Higher PPIX 
levels were measured when more iron was available for hemoglobin synthesis. Since in EPP 
patients the ALAS2 mRNA was found to be enhanced, iron supplementation could lead to an 
increase in ALAS2 protein translation due to a de-repression of the IRE-IRP mediated transla-
tion block and therefore a stimulated synthesis of PPIX.  
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VI. OUTLOOK 
 
Out of two reasons, it is of great importance to identify good parameters to distinguish EPP patients in 
need of extra iron versus patients with a low hemoglobin but stable iron metabolism: Both iron defi-
ciency and iron overload are harmful to the body, however the fate of iron in EPP patients is not un-
derstood at the moment – a block of resorption might account for the low iron values as well as an iron 
loss by unknown mechanism or its deposition in the liver or other organs. Secondly, since our studies 
showed a mechanism to explain exacerbated light sensitivity under iron supplementation by an en-
hanced ALAS2 expression, iron can trigger PPIX production and subsequently liver damage by PPIX. 
In my view, iron in EPP has to be seen as not only a simple substrate of FECH reaction, but as a factor 
exhibiting a regulatory function on many levels of metabolic regulation. In erythroid heme synthesis, 
iron plays a regulatory role at the first and rate-limiting enzyme by the regulation by the IRE/ IRP –
system. Additionally, we demonstrated a role of iron in splice regulation of intron 3 of FECH. Iron ex-
hibits its regulatory role as a substrate of the iron-dependent dioxygenase Jmjd6. Since Jmjd6 modifies 
the common splice factor U2AF65, an effect on the splicing of other genes was demonstrated by others 
as well 213;214. It will be fascinating to search for a conclusive hypothesis to connect the genes regulat-
ed by this mechanism with a response of the body to different metabolic conditions.  
A better understanding of the splicing of FECH intron 3 and the necessary and / or significant se-
quence features could enable a therapy based on splice modification – an approach which could be 
used in over 97% of all EPP patients due to the shared sequence of the low expression allele. Howev-
er, targeting the hematopoietic cells in the bone marrow with a possibly effective substance might turn 
out to be a big challenge.  
Another treatment option could be the down regulation of ALAS2, the first and rate-limiting enzyme 
of heme biosynthesis which was demonstrated by us to be enhanced in EPP. A first step would be to 
measure ALAS2 mRNA, protein and activity in EPP mouse models to elucidate the mechanism of the 
enhancement and enable to test possible treatments.  
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Abstract – The third intron of human ferrochelatase (FECH) gene contains according to NCBI, a poly-C (11) and a poly-T 
(24) tracts which are located approximately 900 bp upstream from the known splice modulating SNP IVS3-48 c/t. 
Ferrochelatase catalyses the last step in heme biosynthesis and a deficiency of this enzyme results in the hereditary disorder 
of erythropoietic protopoprhyria (EPP). During the course of mutation analysis in the FECH gene among EPP patients, we 
observed variations in the length of the poly-C and poly-T tracts. To study these variations, we analyzed a total of 54 
individuals of Swiss and Israeli origins. Among them, 37 were control subjects (23 individuals with the genotype t/t and 14 
with the genotype c/t), 10 were unrelated EPP patients (genotype c/M) and 7 were unrelated asymptomatic mutation carriers 
(genotype t/M). The length of poly-C tract varied from 10 to 16, that of poly-T tract from 22 to 24 in the study cohort. 
Statistic analysis showed that the low-expressed FECH allele (IVS3-48c) is associated with poly-C12, C13 and C15 and 
poly-T22. In addition, the segregation of poly-C and poly-T tracts was studied in two Israeli EPP families. Instabilities, as 
seen by both insertion and deletion of one nucleotide between two generations, were observed only in the poly-T tract. The 
function of the poly-C and poly-T tracts are yet to be explored. 
 
Key words:  
 
 
 
INTRODUCTION 
 
Erythropoietic protoporphyria (EPP, 
OMIM#177000) is a hereditary disorder of the 
heme biosynthetic pathway. The affected enzyme 
ferrochelatase (FECH, EC 4.99.1.1) catalyzes the 
insertion of iron into protoporphyrin IX to form 
heme. As the result of ferrochelatase deficiency, 
a large amount of protoporphyrin accumulates in 
the body and is responsible for the clinical 
symptoms of cutaneous photosensitivity in EPP 
patients (1). In approximately 93% of the cases, 
EPP patients carry a c/M genotype i.e., a mutated 
FECH allele (M) in trans to a low-expressed 
allele. This low allele is characterized by a c-
variant (c) at a polymorphic site in intron 3 
(IVS3-48 c/t). The resulting enzyme activity in 
patients is ∼35% of that of normal individuals.  
 
Individuals with a t/M genotype i.e., a 
combination of a normal IVS3-48t allele (t) with 
an M allele, show a 50% reduction in the enzyme 
activity, without clinical symptoms of EPP. Both 
t/t and c/t genotypes present neither biochemical 
nor clinical signs of EPP (4). About 4% of the 
EPP cases are recessive with one mutation on 
each of the two FECH alleles. Another 3% of the 
cases are the so called variant EPP in which 
deletions in the 5-aminolevulinate synthase 2 
(ALAS2) gene were found (11). 
The third intron of human ferrochelatase 
(FECH) gene contains a poly-C and a poly-T 
tract which are located approximately 900 bp 
upstream from IVS3-48. According to the 
sequence data from NCBI, the length of these 
tracts are 11 for poly-C and 24 for poly-T 
(accession number NT025028). During the 
course of mutation analysis in the FECH gene
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Figure 1. Examples of electropherograms showing various poly-C and poly-T alleles. The alleles are indicated by asterisks 
(*). The vertical lines align identical peaks among different electropherograms. 
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Table 1  Information on the study cohort of 54 unrelated individuals 
 
Origin 
Genotype 
t/t t/M c/t c/M 
Swiss 9 (unrelated controls) 5 (from unrelated EPP 
families)* 
5 (unrelated controls) 10 (from unrelated 
EPP families)* 
Israeli 10 (unrelated controls) 
4 (unrelated family 
members: individual 3 
and 4 from Family 1; 
individual 3 and 7 from 
Family 2; see Fig.2) 
2 (unrelated family 
members: individual 2 
from Family 1; 
individual 2 from 
Family 2)  
8 (unrelated controls) 
1 (individual 1 from 
Family 1) 
- 
total 23 7 14 10 
* The individuals are not related to each other. 
 
 
 
 
 
Table 2  Distribution of poly-C alleles among EPP patients, carriers and control subjects (n= 54) 
Length 
of polyC 
Genotype t/t and t/M Genotype c/t and c/M calculated frequency (%)* 
t/t t/M t/t & t/M c/t c/M c/t & c/M t Diff c-t 
C10 11 3 14 1 0 1 23.3 -21.3 
C11 7 1 8 0 0 0 13.3 -13.3 
C12 9 5 14 14 12 26 23.3 30.8 
C13 7 2 9 6 6 12 15.0 10.0 
C14 2 1 3 0 0 0 5.0 -5.0 
C15 9 1 10 7 2 9 16.7 2.1 
C16 1 1 2 0 0 0 3.3 -3.3 
sum 46 14 60 28 20 48 100 0 
 
* The frequency of t-associated alleles was based on the frequency observed in the combined M/t and t/t genotypes; the 
difference c-t was calculated from the observed frequency in the c/t and M/c genotype after subtraction of the frequency of 
the (t/t and M/t) genotype. For example, for the C10 allele, the calculated t allele frequency equals 14/60 x 100% = 23.3; Diff 
c-t = (1/48 x 100%) – 23.3 = -21.3. Positive numbers indicate over-representation and negative under representation of these 
alleles in the c/t genotype assuming an identical distribution of poly-C alleles in the t/t and c/t genotype.  
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Figure 2. Genotypes of poly-C and poly-T tracts from 54 unrelated individuals of EPP patients, carriers and of control 
subjects. 
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among EPP patients, we observed variations in 
the length of the poly-C and poly-T tracts. In this 
study, we analyzed these variations among 
individuals with the four above-mentioned 
genotypes, t/t, c/t, t/M and c/M. 
 
MATERIALS AND METHODS 
Study cohort 
A cohort of 54 unrelated individuals including EPP 
patients, carriers and control subjects was studied. The 
detailed information on the individuals included, of both 
Swiss and Israeli origins is given in Table 1. None of the 
individuals shared any alleles with another individual within 
this cohort. In addition, two previously published Israeli 
EPP families and 5 Swiss EPP families were analyzed (8,9, 
Fig.3, Table 4). All EPP patients and carriers had 
documented mutations in the FECH gene. 
 
Analysis of poly-C and poly-T tracts 
Genomic DNA from each individual was amplified by 
PCR using fluorescence labeled primers. For amplification 
of the poly-C tract, primers 5’-FAM-CCT TGC ACT CCC 
AGT TAT C-MGB-3’ and 5’-TAC CTT CAC ATT TGT 
GTA ACG-3’ were used. And for amplification of the poly-
T tract, primers 5’-FAM-TCG TTA CAC AAA TGT GAA 
GGT-MGB-3’ and 5’-GGA GGG ATG GCA TTA GGA-3’ 
were used. The lengths of the PCR products were analyzed 
on the ABI Prism 310 genetic analyzer (Applied 
Biosystems, Foster City, California, USA). To determine the 
number of “C”s and “T”s in the poly-C and poly-T tracts, 
the electropherograms of probands were compared with that 
of “markers”. These markers were generated by cloning of 
the non-fluorescent PCR products from a control subject 
into pBluescript. The number of “C”s or “T”s in individuals 
clones was determined by sequencing. Three poly-C clones, 
C10, C12 and C13, and three poly-T clones, T19, T21 and 
T22, were obtained. Purified plasmid DNA from the each of 
the six clones were amplified with fluorescence labeled 
primers before being analyzed on the ABI Prism 310 genetic 
analyzer. 
Analysis of the IVS3-48c/t polymorphism was 
performed as previously described (9). 
 
Statistical analysis 
Non-identity of the distribution of the variable poly-C 
and poly-T tracts among the polymorphic IVS3-48 alleles 
was tested by Chi-square test including Monte Carlo 
simulation of the multinomial sampling distribution 
(http://faculty.vassar.edu/lowry/VassarStats.html). 
 
RESULTS 
 
Identification of different poly-C and poly-T 
genotypes 
The analysis of the 54 unrelated individuals 
and members of the seven Israeli and Swiss EPP 
families, identified a total of 18 different poly-C 
and 5 different poly-T genotypes. As shown in 
Figure 1, the electropherogram of each genotype 
consists of one or two major peaks that are 
surrounded by a number of stutter peaks. Due to 
overlapping between major and stutter peaks, the 
assignment of individual alleles in each 
electropherogram was only possible with the help 
of “markers”. As described in the Materials and 
Methods section, these “markers” were made 
from poly-C and poly-T clones with a known 
number of the respective nucleotides. 
 
Distribution of poly-C and poly-T among 
genotypes t/t, M/t, c/t and c/M 
The 54 unrelated individuals carried 
different genotypes with respect to IVS-48 i.e., 
23 individuals with the t/t genotype, 7 with the 
t/M genotype, 14 with the c/t genotype and 10 
with c/M genotype (Table 1). Among them, all 
individuals with the M/t and c/M genotypes were 
selected from different EPP families. 
The poly-C and poly-T genotypes of the 54 
unrelated individuals were assigned according to 
the electropherograms shown in Figure 1. 
Among the 108 alleles of this cohort, seven 
different poly-C alleles, C10 to C16, and three 
different poly-T alleles, T22, T23 and T24, were 
identified. The allelic distribution of poly-C and 
poly-T among the four IVS-48 genotypes are 
shown in Table 2 and Table 3, respectively. 
To obtain an overview on the genotype 
distribution among the 54 individuals, the poly-C 
genotype (a combination of two poly-C alleles) 
from each individual was plotted against the 
poly-T genotype (a combination of two poly-T 
alleles) (Figure 2). Except for C10/10 and 
C16/16, the remaining 16 poly-C genotypes (see 
Figure 1) were found among the 54 individuals. 
All five poly-T genotypes (see Figure 1) were 
observed among the 54 individuals. Variations in 
poly-C among EPP patients (genotype c/M, n= 
10) differ significantly from the control group 
(genotype t/t, n=23; p<0.001). However, no 
statistically significant difference was found in 
poly T (p=0.23). 
 
Poly-C and poly-T in the low-expressed FECH 
allele 
To study the relationship between low-
expressed FECH allele (IVS3-48c) and poly-
C/poly-T tracts, the results in Table 2 and 3 were 
analyzed by chi-square test separately. Since 
both genotype t/M and t/t are in fact homozygous 
t/t at IVS3-48, the poly-C/poly-T results from 
these two genotypes were combined (see column 
“t/t & t/M” in Table 2 and 3). Likewise, c/t 
individuals were combined with c/M individuals 
(see column “c/t & c/M” in Table 2 and 3). Chi-
square test was then performed in these data sets.  
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Table 3  Distribution of poly-T alleles among EPP patients, carriers and control subjects (n=54) 
Length 
of polyT 
Genotype t/t and t/M Genotype c/t and c/M calculated frequency (%)* 
t/t t/M t/t & t/M c/t c/M c/t & c/M t Diff c-t 
T22 12 5 17 13 8 21 28.3 15.4 
T23 31 7 38 15 12 27 63.3 -7.1 
T24 3 2 5 0 0 0 8.3 -8.3 
sum 46 14 60 28 20 48 100 0 
*see table 2. 
 
Table 4  Haplotypes of the IVS3-48c allele in seven Swiss and Israeli EPP families 
 
Haplo- 
types 
EPP families 
A B C Israeli 2(1) Israeli 1 D E Israeli 2(2) 
poly-C 12 12 12 13 12 12 13 13 
poly-T 22 22 22 22 23 23 23 23 
IVS3-48 c c c c c c c c 
Swiss families: A, B, C, D and E (one member of families A and E with genotype t/M are included in Table 1; one member 
of families B, C and D with genotype c/M are included in Table 1);   
Israeli 1: Family 1 in Figure 2;  
Israeli 2 (1): the first “c” allele in individual 1 of Family 2 (see Figure 2);  
Israeli 2 (2): the second “c” allele in individual 1 of Family 2 (see Figure 2). 
 
 
 
 
The results showed that the distribution of poly-
C alleles was significantly different between the 
t/t genotype (including M/t) and the c/t genotype 
(including (M/c) (p<0.0001). The calculated 
frequency of different poly-C alleles based on the 
frequency observed in the t/t genotypes showed 
that in the c/t genotype, C12, C13 and C15 were 
more frequent and the other alleles were less 
frequent than expected (Table 2). With the same 
approach, T22 was found to be associated with 
the IVS3-48c allele (c) (p<0.0149; Table 3). 
To verify the results of chi-square test, 
haplotyping analysis was performed among the 
seven Israeli and Swiss EPP families. Eight 
different “poly-C/poly-T/IVS3-48c” haplotypes 
were resolved including two from Israeli Family 
1 (Table 4, Figure 3). Among these eight 
haplotypes, C12 and C13 appeared 5 and 3 times, 
respectively. This result is consistent with that of 
chi-square test. On the other hand, T22 and T23 
both appeared 4 times among the eight 
haplotypes, although the chi-square test only 
indicated an association between T22 and the 
low-expressed allele (c). 
 
DISCUSSION 
 
PCR amplification of mononucleotide repeat 
artificially introduces insertions and/or deletions 
within the repeat which give rise to a mixture of 
products in different lengths (2). As we 
experienced, sequencing of such a mixture of 
PCR products does not produce any informative 
results. To overcome this analytical difficulty, we 
amplified the poly-C and poly-T by PCR using 
fluorescently labeled primers and analyzed the 
products by capillary electrophoresis. However, 
the PCR products - a mixture as they remain, 
appear as complex patterns in the 
electropherograms. Each of the electropherogram 
contains one or two major peaks representing 
homo- or heteroallele in diploids such as human. 
The identification of heteroalleles (major peaks) 
could be hampered by the presence of stutter 
peaks (PCR artifacts). With respect to the poly-C 
tract, heteroalleles can be readily recognized if 
the length difference between the two alleles is > 
3 nucleotides (examples are C10,13, C10,14, 
C10,15, C11,15, C11,16, C12,15, C13,16 in 
Figure 1). With the help of “markers”, we were  
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Figure 3. Segregation of poly-C, poly-T and IVS3-48c/t in two Israeli EPP families. The mutated and low-expressed FECH 
alleles are highlighted in red and yellow, respectively. Changes, either insertion or deletion, in the length of poly-T tract 
between two generations are underlined. In Family 2, two different IVS3-48 c alleles are represented by c1 and c2, 
respectively. 
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able to assign the remaining homo- and 
heteroalleles. 
In the poly-T tract, a difference of only one 
nucleotide between two alleles has been observed 
in the study subjects. The identification of 
different genotypes was made possible with the 
help of “markers” (Figure 1). Another 
observation on the poly-T tract is its instability 
between two generations. As shown in Figure 3, 
both deletion and insertion of a single T occurred 
in the two Israeli families (underlined numbers). 
In a recent publication by Thompson and 
Salipante, the authors demonstrated the use of a 
software, named PeakSeeker, in genotyping of 
mononucleotide tracts (10). A computer 
algorithm such as PeakSeeker, could facilitate 
the interpretation of genotypes of 
mononucleotide repeats and thereby permits a 
more widely use of this type of highly 
informative markers in genetic research. 
Based on both haplotypic and phylogenic 
analyses, Gouya et al came to a conclusion that 
the low-expressed IVS3-48c allele (c) arose from 
a single recent mutational event that occurred on 
the normal FECH allele IVS3-48t (t) some 
40,000 to 60,000 years ago (4). The finding of 
this study supported the notion of IVS3-48c 
being a younger haplotype compared to IVS3-
48t. As visualized in Figure 2, genotypes 
encompassing an IVS3-48c allele i.e., c/M and 
c/t shown in red and green symbols, respectively, 
are located closely to each other. In contrast, the 
blue and yellow symbols representing genotypes 
t/t and t/M, respectively, are more widely spread. 
The genotype distribution, as well as the result of 
the statistical analysis, suggest that the IVS3-48c 
haplotype is associated with fewer variations in 
the poly-C and poly-T tract compared to the 
IVS3-48t haplotype. The fewer variations were 
compatible with less meiotic or replicative 
modifications due to the younger age. The fewer 
variations could be further interpreted by the fact 
that the poly-C and poly-T tracts are located in a 
close vicinity to IVS3-48. According to a study 
of Gouya et al, the IVS3-48c variant is located 
within an extended haplotype [GGTA] spanning 
from the 5’ noncoding region (-3670A/G) to 
intron 4 (IVS4-1197C/A) (5). The finding of the 
associated poly-C and poly-T alleles fit within 
this haplotype. 
Deletions in the poly-T tract resulting in 
aberrant splicing, have been observed in cancer 
related genes such as ATM and MRE 11 (3,7). 
The instability of poly-T tract has therefore been 
suggested to play a role in the development of 
cancer. In general, homopolymer tracts are 
significantly over-represented and more widely 
spread in the genome than simply by chance 
(6,12). However, any possible functions of the 
poly-C and poly-T tracts of the FECH gene in 
the low expression mechanism remain to be 
studied. 
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Erythropoietic protoporphyria (EPP) results from partial deﬁciency of ferrochelatase (FECH). Genetically, EPP
patients differ from asymptomatic mutation carriers at the unmutated FECH allele, the expression of which is
modulated by single nucleotide polymorphism IVS3-48C/T. The IVS3-48C genotype, which is present among
patients, leads to correct splicing of 60% of the pre-mRNA and to alternative splicing of 40%, the latter
mRNA-product being destroyed by nonsense-mediated decay. An IVS3-48T genotype generates 80% correct and
20% aberrant products. Our study demonstrated that under iron deﬁcient conditions, the aberrant splice product
was increased to 56% and 50% of total FECHmRNA in erythroleukemic K562 and lymphoblastoid cell lines, respec-
tively, both being homozygous for IVS3-48T. Concomitantly, FECH protein was decreased. Iron deﬁciency had less
effect on the FECH splice ratio in an IVS3-48C/C lymphoblastoid cell line. Effects similar to iron deﬁciencywere gen-
erated by siRNA knockdown of either splicing factor U2AF65 or Fe(II)- and 2-oxoglutarate-dependent dioxygenase
Jumonji domain-containing protein 6 (Jmjd6),which interactswith U2AF65 by lysyl-hydroxylation. Based on these
results, we propose that the availability of iron, a co-factor of Jmjd6,modulatesU2AF65-lysyl-hydroxylation. This in
turn, inﬂuences the relative amounts of correct and aberrant FECH mRNA splice products and thus, regulates the
FECH enzyme activity.
© 2013 Elsevier Inc. All rights reserved.
Introduction
Ferrochelatase (FECH), the last enzyme of the heme biosynthesis
pathway, catalyzes the insertion of ferrous iron into the heme precursor,
protoporphyrin IX (PPIX). A partial deﬁciency of ferrochelatase causes
erythropoietic protoporphyria (EPP, OMIM 177000), an inherited
disorder which is characterized by painful photosensitivity due to
the accumulation of PPIX in the skin. Intron 3 of the ferrochelatase
pre-mRNA can be either correctly spliced or alternatively spliced at
an aberrant site located 63 bp upstream from the correct splice site
(IVS3-63). The aberrant splicing results in an mRNA product which
contains an additional 63 bp intronic sequence. Due to the presence
of a premature termination codon (PTC) within this insertion, the
aberrant splice product is subjected to nonsense mediated decay
(NMD) and does not serve as a template for protein synthesis. In a
minigene assay, it was found that a single nucleotide polymorphism
(SNP) at position−48 of intron 3 determines the relative amount of
normal and aberrant splice products [13]. If a T is present at the−48
position (IVS3-48T), the more frequent genotype in the general pop-
ulation, 10 to 20% of the FECH pre-mRNA is aberrantly spliced. In an
IVS3-48C genotype, however, the amount of aberrant splice product
is increased to 30–40% of the total transcripts. The combination of
IVS3-48C in trans to a deleterious mutation in the FECH gene causes
EPP, whereas individuals having an IVS3-48T allele in trans to a
mutated ferrochelatase allele are asymptomatic [12].
The promoter region of human FECH gene contains sequences for
recognition of both ubiquitous Sp1 family of transcription factors,
as well as for erythroid-speciﬁc trans-acting factors NF-E2 and
GATA-1 [43]. Regulation of ferrochelatase occurs at the transcrip-
tional level, in that the Sp1-driven promoter with a minimal size of
150-bp directs expression of the FECH gene in all types of cells, and
the erythroid-speciﬁc promoter (approximately 4 kb in size) con-
trols upregulation of ferrochelatase during erythropoiesis [31]. The
C-terminus of ferrochelatase contains 4 cysteine residues arranged in
a sequence (C-X7-C-X2-C-X4-C), which is a ﬁngerprint for a [2Fe–2S]
binding motif [6]. Mutations in these cysteine residues were associated
with EPP [38]. However, the exact role of this Fe–S cluster in the enzyme
reaction remains unclear [2].
Cellular iron storage and uptake are coordinately regulated post-
transcriptionally by iron-regulatory proteins 1 and 2 (IRP-1 and IRP-2).
When iron supply is limited, IRP blocks the translation of ferritin mRNA
and stabilizes the mRNA of transferrin receptor by binding to iron-
responsive elements in thesemRNAs. The regulatorymechanism ensures
an adequate supply of iron for the synthesis of hemoproteins and other
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iron-containing molecules and at same time, prevents iron overload
which is hazardous for the organism [34].
A regulatory function of alternative splicing with a PTC, termed
regulated unproductive splicing and translation (RUST), has been
described in a number of other genes [27]. The biosynthesis of heme
is tightly regulated since its intermediary porphyrins as well as the
end product heme are toxic to the organism if present in excess
(reviewed in references [2,24,25]). Is the alternative splicing of intron 3
of the FECH gene, and therefore the amount of ferrochelatase enzyme,
regulated? To study this possibility, we conducted in vitro experiments
in cultured cells and demonstrated that iron, a substrate of ferrochelatase,
has an inﬂuence on the amounts of correct and aberrant transcripts of the
FECH gene as well as on the level of ferrochelatase protein. We also
explored the mechanism by which iron regulates splicing of intron 3 of
the FECH gene.
Experimental procedures
Mutational analysis and genotyping among EPP patients and healthy donors
Mutational analysis in the FECH gene and genotyping of IV3-48C/T
were performed among eight EPP patients in connection with the
porphyria diagnosis to which all patients gave their informed consent.
Informed consent was also obtained from eight healthy donors with
regard to the testing of IVS3-48C/T. Peripheral blood samples were
obtained from all individuals. DNA isolation, PCR ampliﬁcation and
sequence analysis were performed as previously described [37].
Seven of the EPP patients were heterozygous for one of following
mutations, p.Q59X, 212–213 ins T, 580–584delTACAG and p.S151P.
Nomutation was found in the coding exons and exon–intron boundaries
of the FECH gene of one EPP patient although both clinical and bio-
chemical evidences were sufﬁcient to support the EPP diagnosis in
this patient (Supplementary Table). All EPP patients were heterozy-
gous for IVS3-48C/T, whereas all healthy donors were homozygous
for IVS3-48T/T.
Establishing lymphoblastoid cell lines
Additional blood samples were collected from one of the EPP
patients,who carried the p.Q59Xmutation in trans to IVS3-48C (genotype
M/C) and from one of the healthy donors (genotype T/T). p.Q59X is the
most frequent mutation in Switzerland [39]. This null-allele mutation is
located in exon 2 of the FECH gene. A blood sample was also collected
from another individual whowas homozygous for IVS3-48C/C (genotype
C/C) after informed consent. Lymphoblastoid cell lines were established
from these three individuals by transformation of the mononuclear cells
with EBV according to a standard procedure [8].
All studies involving human subjects were approved by our local
ethics committee.
Cell culture
EBV-immortalized human lymphoblastoid cell lines and the
human erythroleukemic K562 cell line (American Type Culture Collec-
tion) were cultured in RPMI 1640 medium (Gibco, Invitrogen, Carlsbad,
California, USA) supplemented with 10% fetal calf serum (Bioconcepts
Amimed, Allschwil, Switzerland) and streptomycin/penicillin (Gibco,
Invitrogen) at 37 °C under 5% CO2. The cells were split 1:5 every third
day to maintain an exponential growth phase. In each experiment, one
million cells were seeded in 6-well cluster plates. Upon addition of differ-
ent chemical substances, the cells were incubated for 24 h, 48 h or 60 h.
Chemicals
Both deferoxamine mesylate salt (DFO) and ferric ammonium citrate
(FAC; ammonium iron (III) citrate) were purchased from Sigma-Aldrich
(St. Louis, Missouri, USA); dimethyloxalylglycine (DMOG) from Bio-
Science Products (Buchs, Switzerland) and 1,2-dimethyl-3-hydroxy-
4-pyridone (deferiprone) from ACROS Organics, Thermo Fisher Scientiﬁc
(Waltham, MA, USA). All chemicals were dissolved in ddH20 and sterile
ﬁltered (Millipore, 22 μm ﬁlters) to obtain stock solutions. The stock
solutions were directly applied to the cell culture medium. Ready-
made cycloheximide (CHX) solution (100 mg/ml in DMSO) was
purchased from Sigma-Aldrich. In cell culture experiments, the CHX so-
lution was further diluted with DMSO to obtain desired concentrations.
The concentration of DMSO in all cell culture media was 0.2%.
RNA isolation and real-time PCR
Total RNA was extracted by using the RNeasy Mini Kit according to
the manufacture's protocol (Qiagen, Hilden, Germany). The protocol in-
cludes an on-columndigestion of genomic DNA. Nuclear and cytoplasmic
RNA was separated by using the SurePrep Nuclear or Cytoplasmatic RNA
Puriﬁcation Kit (Thermo Fisher BioReagents, Waltham, MA, USA). The
quality of RNA was evaluated using RNA Nano chips on Agilent 2001
bioanalyzer (Agilent Technologies, Santa Clara, California, USA). RNA
was then quantiﬁed on Nanodrop 2000c Spectrophotometer (Thermo
Fisher Scientiﬁc). One-thousand nanograms of total RNA from each isola-
tion was reverse transcribed into cDNA by using the Transcriptor First
Strand cDNA Synthesis Kit and anchored-oligo(dT)18 primer (Roche
Diagnostics Inc., Basel, Switzerland).
For quantiﬁcation of cDNA, real-time PCR was performed on ABI
PRISM 7000 using gene speciﬁc primers and TaqMan probes (Applied
Biosystems, Life Technologies, Carlsbad, California, USA). One-twentieth
of the resulting cDNA was used in each reaction. All measurements
were done in triplicate. To differentiate between normally and aberrantly
spliced FECH mRNAs, two separate real-time PCR TaqMan assays were
employed. The amount of normally spliced product was measured by
using a commercial TaqMan primer-probe set which is localized on the
exon 3-exon 4 boundary (Hs01555261_m1, Applied Biosystems, Life
Technologies). Quantiﬁcation of the aberrant splice product was carried
out by using a self-designed primer–probe set (see below). Transcripts
of U2AF65, Jmjd6 and TFRC (transferrin receptor 1) were quantiﬁed by
using commercially available TaqMan real-time PCR primer-probe
sets (Hs00200737_m1, Hs00397095_m1 and HS00951083_m1) from
Applied Biosystems, Life Technologies. Beta-actin (Hs99999903_m1)
was used as an endogenous control to calculate the amount of each tran-
script. Speciﬁcally, the threshold cycle (Ct) value from a particular tran-
script was subtracted by that of β-actin to obtain a delta-Ct value.
Arbitrary unit (a.u.) was deﬁned as 2−ΔCt × 103.
Real-time PCR quantiﬁcation of aberrantly spliced FECH mRNA
To quantify the amount of aberrantly spliced FECH mRNA, a set of
TaqMan primer–probe was designed to detect speciﬁcally a region of
FECH mRNA containing both exons 3 and 4 as well as the 63 bp inser-
tion between the two exons. Primer ferroins2f: 5′-AGA CCT CAT GAC
ACT TCC TAT TCA GA-3′. Primer ferroins2r: 5′-CGA TGA ATG GTG CCA
GCT T′-3′. Probe ferroins2: 6-FAM-TAA GCT GGA ATA AAA TCC
ACT-MGB. The efﬁciency of the real-time PCR reaction was proven to
be closed to 100% (slope ≈ 3.3). No signals were detected when ampli-
fying genomic DNA samples. All mRNAs, unless otherwise indicated,
were detected at the steady state levels without inhibition of the non-
sense mediated decay.
siRNA transfection assays
For transfection of cells with siRNA, 300 000 K562 cells were plated
in 6-well plates containing 2 ml RPMI 1640 medium supplemented
with 10% fetal calf serum without antibiotics. Stocks (40 μM) of pre-
annealed siRNA against Upf1, U2AF65 and Jmjd6 mRNA were diluted
in Oligofectamine reagent and OptiMem (Invitrogen) according to the
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manufacture's protocol. Five-hundred microliters of themix was added
drop wise to the cells. Incubation time was between 48 h and 72 h.
The sequence of siRNAs are as follows: Upf1_1s: 5′-GAG AAU CGC
CUA CUU CAC UTT-3′ [33]; Jmjd6_1: 5′-GAGGGAACCAGCAAGACGA-3′
[5]; U2AF2 (U2AF65): 5′-GCA CGG UGG ACU GAU UCG U-3′ [32].
Western blot
The cytosolic andmembrane fractions of the cells were separated by
using the QProteome Cell Compartment Kit (Qiagen). The protein con-
centrations in these fractions were quantiﬁed by the benzethonium
chloride method on a clinical chemistry analyzer, Cobas 501 (TPUC3;
Roche Diagnostics Inc., Rotkreuz, Switzerland) [16,29]. Equal amount
of protein from each fraction was dissolved in lysis buffer in a ﬁnal
volume of 15 μl andwas thenmixedwith 5 μl of loading buffer (NuPage
LDS 4× LDS Sample Buffer). The sample (15 μl) was loaded onto a
precast NuPage gel containing 4–12% BisTris (1.5 mm, 15 wells). The
gel was run at a constant voltage of 100 V in an X Cell II Chamber
(Invitrogen). Magic Mark XP Western Blot protein standard was used
as aweightmarker (Invitrogen). Gels were blotted on 0.45 μmNitrocel-
lulose using X Cell II BlotModule (Invitrogen). Themembranewas then
blocked with TBS Blotto A Blocking Reagent (Santa Cruz Biotechnology
Inc., Santa Cruz, USA.) for 40 min. Membranes were ﬁrst incubated
with primary antibodies over night at 4 °C, then washed twice with
PBS-Tween and ﬁnally incubated with the secondary antibody for
1 h at room temperature. The following antibodies were used:
ferrochelatase primary antibody (sc-49663; in 1:200 dilution) and
secondary antibody donkey anti goat IgG-HRP (sc-2020; in 1:2000
dilution; Santa Cruz Biotechnology Inc.). Beta-actin primary antibody:
monoclonal anti beta-actin (A5316; in 1:5000 dilution) and secondary
antibody: anti-mouse IgG peroxidase antibody produced in goat
(A9917; in 1:2000 dilution; Sigma-Aldrich). Bands were visualized by
staining the membranes with Sigma FAST DAB horse radish peroxidase
substrate (Sigma-Aldrich). Membranes were photographedwith Quan-
tity One device (Bio-Rad laboratories, INC., Hercules, California, USA).
The intensities of the bands were densitometrically quantiﬁed with
Image J-software (http://rsbweb.nih.gov/ij/download.html) [1].
Statistical analysis
Data were analyzed by either t-test or one-way ANOVA followed
by Bonferroni post hoc correction using SPSS version 19, IBM-SPSS,
Chicago, IL. A two-sided p ≤ 0.05 was considered to be statistically
signiﬁcant.
Sequence comparison
A partial sequence of the human FECH gene containing intron 3 and
exon 4 was imported into the UCSC Genome Browser (http://genome.
ucsc.edu/) [11,19–21,36] in order to search for the corresponding
sequences among other species. The following sequences were
obtained from the USCS Genome Browser: Chimp: Oct. 2010 (CGSC
2.1.3/panTro3); Gorilla: May 2011 (gorGor3.1/gorGor3); Orangutan:
July 2007(WUGSC 2.0.2/ponAbe2). In addition, the sequence of Homo
sapiens (NT025028) was obtained from NCBI (http://www.ncbi.nlm.nih.
gov/gene/?term=FECH). The extracted sequences were aligned by the
software CLUSTAL W (http://www.ch.embnet.org/software/ClustalW.
html) [26,41].
Results
The amounts of correctly and aberrantly spliced FECHmRNA are determined
by the genotype with regard to IVS3-48C/T
First, we tested whether the results from the minigene assay are re-
producible in vivo. To this aim, the IVS3-48 genotypes of eight healthy
donors and eight EPP patients were determined by sequencing of the
FECH gene as previously described [37]. All EPP patients were heterozy-
gous for IVS3-48C/T, whereas all healthy donors were homozygous for
IVS3-48T/T. To measure the amount of aberrantly spliced FECH mRNA
in the peripheral blood cells of these individuals, a quantitative TaqMan
real-time PCR assay was developed. In addition, a commercially avail-
able TaqMan assay was employed to quantify the amount of correctly
spliced FECH mRNA (the primers and probe are located at the exon 3–
exon 4 boundary). The results showed a clear genotype dependency.
In the control subjects of T/T genotype, the amount of aberrantly spliced
mRNA comprised 21.5% (SD = 7.5%) of the total FECH mRNA, as op-
posed to 34.5% (SD = 5.1%) in EPP patients (an IVS3-48C allele in
trans to a mutated FECH allele; p b 0.005; Fig. 1A). The clear genotype
dependency conﬁrmed previous ﬁndings in mini-gene models and
lymphoblastoid cells by Gouya et al. [13].
Next, we measured the levels of two FECH transcripts in lympho-
blastoid cell lines generated from individuals with genotypes T/T, C/C
and M/C (M stands for mutated allele). The lymphoblastoid cell line
with the T/T genotype showed the highest amount of correctly spliced
FECH mRNA i.e., 88.3% (SD = 1.9%, n = 7) of the total amount of tran-
scripts at the steady state level. The aberrant FECH mRNA accounted
therefore for 11.7% of the total amount of transcripts in this cell line.
In the C/C cell line, the ratio between normal and aberrant splice products
was 84.0% to 16.0% (SD = 3.9%, n = 5). A slightly higher amount of
aberrant splice product i.e. 18.9% (SD = 4.3%, n = 3) of the total tran-
scripts was observed in the M/C cell line (Fig. 1B).
Because the metabolic defect of EPP mainly manifests in late
erythropoiesis, a human erythroleukemic cell line (K562) displaying
most of the features of erythropoiesis was investigated [3,23,28]. The
K562 cell line, also having a T/T genotype with respect to IVS3-48 as
determined by sequence analysis, showed 18.6% aberrantly spliced
FECH mRNA (SD = 3.9%, n = 4; Fig. 1B).
As stated above, the aberrantly spliced FECH mRNA contains a PTC
in its additional 63 bp intronic sequence and is therefore subjected to
nonsense mediated decay (NMD) [13]. To further characterize this
process, we conducted a series of experiments using two different
approaches to inhibit NMD in the K562 cells. In both experiments,
we were able to demonstrate a dose-dependent accumulation of the
aberrant splice product.
In the ﬁrst experiment, cycloheximide (CHX) was used, a com-
pound that blocks protein synthesis and therefore inhibits NMD in
eukaryotic organisms. The experimental conditions i.e., concentra-
tions (from 50 to 100 μM) and incubation time (6 h) had been previ-
ously optimized for the K562 cells in our laboratory. Fig. S1A in
Appendix A shows the results of CHX treatment of K562 cells. An in-
crease of 5.6 fold in the amount of aberrant splice FECH was observed
in cells treated with 100 μM CHX compared to untreated cells (DMSO
alone). Interestingly, under the same condition, the amount of normal
FECH transcript was also increased by 1.7 fold, which indicated that the
half-life of normal FECH mRNA was extended. This could be explained
by the fact that CHX blocks protein translation and therefore slows
down the decay of normal FECH mRNA, which occurs after several
rounds of translation [9].
Up-frameshift protein 1 (UPF1) is an evolutionarily conserved
protein with RNA/DNA-dependent ATPase and RNA helicase activity.
It plays an essential role in NMD which eliminates aberrant mRNAs
harboring PTC [15]. In our second experiment, Upf1 was selectively
knocked down by siRNA. The conditions (30 and 60 nM, 72 h) used
in the siRNA experiments had also been optimized previously. As
shown in Fig. S1B (the left panel), transfection of K562 cells with
siRNA against Upf1 resulted in a maximum of 54.9% reduction in its
mRNA level (from 20.48 arbitrary units, SD = 8.27 mocked condition
to 11.25 arbitrary units, SD = 3.21 under 30 nM siRNA treatment).
With respect to the FECH transcripts, the aberrantly spliced mRNA in-
creased from 3.4 arbitrary units (SD = 0.9) in UPF1-mocked transfec-
tion to 7.4 arbitrary units (SD = 1.4) under 60 nM siRNA against UPF1.
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The amount of aberrantly spliced mRNA was signiﬁcantly different
among the three conditions (p b 0.005). Thereby, the post hoc test
showed that the effect of 60 nM siRNA differed signiﬁcantly from that
of both 0 and 30 nM siRNA. The levels of correctly spliced FECH tran-
script were not affected, which lay between 14.8 (SD = 4.1; mock)
and 15.3 arbitrary units (SD = 4.0; 30 nM siRNA) (n = 3; Fig. S1B, the
right panel).
Iron depletion by DFO down-regulates the amount of normally spliced FECH
mRNA and enhances aberrant intron 3 splicing in K562 and lymphoblastoid
cell lines
To test whether iron availability alters the amount of correctly
spliced FECH mRNA, we treated the erythroleukemic cell line K562
(genotype T/T) and lymphoblastoid cell lines of different genetic
backgrounds (genotype T/T, C/C and M/C) with an iron-chelating
agent, deferoxamine (DFO) and measured the amounts of correctly
and aberrantly spliced products by quantitative real-time PCR.
As shown in Fig. 2A, during treatment of K562 cells with DFO at
different concentrations (50, 100 and 200 μM) for 60 h, the proportion
of correctly spliced mRNA decreased from 83.3% (SD = 1.2%; 0 μM) to
43.7% (SD = 5.9%; 200 μM) of the total FECHmRNA, and concurrently,
the aberrantly spliced mRNA increased from 16.7% (0 μM) to 56.3%
(200 μM) of the total FECH mRNA. The difference between 0 μM and
100 μM or 200 μM was statistically signiﬁcant, p b 0.0001 (n = 4).
Similar dose-dependent changes in both the correct and aberrant
products occurred under a concentration range from 0 μM to 100 μM
in lymphoblastoid cell line of the T/T genotype after 24 h of incubation
as shown in Fig. 2B. The correctly spliced mRNA decreased from 90.4%
(SD = 1.1%; 0 μM) to 50.1% (SD = 3.6%; 100 μM) and the aberrantly
spliced mRNA increased from 9.6% (0 μM) to 49.9% (100 μM) of the
total. A higher concentration of DFO (200 μM) did not result in any fur-
ther changes in the splice ratio (correct vs. aberrant products remained
approximately 50%:50%). The difference between 0 μM and 100 μM or
200 μMwas statistically signiﬁcant, p b 0.0001 (n = 3).
Only marginal changes were found in lymphoblastoid cell lines of
both the C/C and M/C genotypes (Figs. 2C and D). After treatment of
the C/C lymphoblastoid cell linewith DFO for 48 h, the correctly spliced
product dropped only slightly, from 84.4% (SD = 3.1%; 0 μM) to 71.3%
(SD = 3.1%; 100 μM) of the total, whereas the aberrantly splice product
increased from 15.6% (0 μM) to 28.7% (100 μM) of the total. The dif-
ference between 0 μMand 100 μMor 200 μMwas statistically signif-
icant p b 0.005 (n = 3; Fig. 2C). In the M/C lymphoblastoid cell line,
the corresponding changes were 81.4% (SD = 3.7%, n = 3) to 64.8%
(SD = 7.8%) and 18.6% to 35.2%. The difference between 0 μM and
100 μM or 200 μM was statistically signiﬁcant, p b 0.05 (n = 3;
Fig. 2D). Similar to the T/T cells, a higher concentration of DFO
(200 μM) did not cause any further changes in the splice ratio in both
the C/C and M/C cell lines.
To test whether the DFO concentrations we used were physiolog-
ically relevant, we measured the expression level of transferrin re-
ceptor 1 (TFRC), a gene known to be regulated by iron, in the K562
cell line under the same conditions. The amount of TFRC mRNA in-
creased signiﬁcantly in response to DFO-induced iron depletion (data
not shown).
To verify the observed effect of DFO on the FECH splice products, a
second iron chelator, deferiprone was tested in the K562 cells (Fig. 3A).
Since three molecules of deferiprone are needed to chelate one mole-
cule of iron, the concentrations of deferiprone used were three times
higher than that of DFO i.e., 0 μM, 150 μM, 300 μM and 600 μM (the in-
cubation time remained at 60 h). The results were similar to that of DFO
treated K562 cells.
Products of ferrochelatase, zinc protoporphyrin IX or heme, did not
have any effects on the ratio between the two splice products. We
were unable to test the effect of one of the substrates of ferrochelatase,
protoporphyrin IX, as it was difﬁcult to handle experimentally due to its
poor solubility in aqueous medium (data not shown).
Neutralization of the DFO effect by iron supplementation in vitro
To test whether the decrease in FECH mRNA and the increase in
aberrant splice product were indeed caused by iron depletion rather
than nonspeciﬁc interaction of DFO with cells, a stoichiometric
amount of iron (ferric ammonium citrate as iron source; FAC), together
with DFO, was added to the culture media.
The four middle panels of Fig. 2 show the results of this experiment
in K562 cells, T/T, C/C andM/C lymphoblastoid cell lines, respectively. In
both K562 and T/T lymphoblastoid cells, the strong effects of DFO as
seen in the left panels, are prevented after treating the cells with DFO
and iron at equimolar concentrations (50 μM, 100 μM and 200 μM)
for the same amount of time as described for DFO alone. More precisely,
under these concentrations, the proportions of the correctly spliced
product were between 76.4% (SD = 2.5%) and 82.5% (SD = 4.8%) of
the total, close to the baseline value (0 μM of both DFO and iron) of
84.5% (SD = 4.3%; K562 cells) and 88.7% (SD = 1.4%; T/T cells). Con-
comitantly, the proportions of aberrantly spliced product remained
near the baseline value. In both the C/C and M/C cell lines, neutraliza-
tions of the effects of DFO were also observed, although the effects of
DFO were much weaker than that in the K562 and T/T cell lines as
shown above. Treatment of iron alone had no effects on splicing in
any of the cell lines as shown in the four right panels of Fig. 2.
In a separate experiment on theK562 cells, a slightly different protocol
was used. Instead of adding DFO and iron simultaneously as described in
the experiment above, DFO and iron were added sequentially to the cul-
ture media. As depicted in Fig. 3B, the K562 cells were ﬁrst grown in
media containing 100 μM of DFO for 24 h. An equimolar concentration
of iron was then added to the culture. The cells continued to grow in
the media containing both DFO and iron for an additional of 24 h before
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Fig. 1. Association between SNP IVS3-48 C/T and the amount of FECH transcripts measured by real-time PCR. (A) Percentage of correct and aberrant FECH splice variants in whole
blood samples of eight healthy controls with the genotype IVS3-48T/T and eight EPP patients with the genotype IVS3-48C/M (mutation in trans to IVS3-48C). (B) Percentage of
correct and aberrant FECH splice variants in K562 cell line (genotype IVS3-48T/T) and in three lymphoblastoid cell lines with the genotypes IVS3-48T/T, C/C and M/C,
respectively. In all ﬁgures, the correct and aberrant splice variants are represented by solid and empty bars, respectively.
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harvesting. As controls, cells grown inmedia containing either DFO alone
for 48 h or iron alone for 24 hwere used, in addition to the no-treatment
control. The result showed a complete reversal of the DFO effect as the
amounts of both correctly and aberrantly spliced products returned to
the baseline value i.e., to that of the untreated cells (n = 3). The overall
signiﬁcancewas p b 0.003,whereby the post-hoc test found only a signif-
icance between the DFO-only treatment and the other three conditions,
but not among the three.
DFO-induced change in FECH mRNA ratio occurs predominantly in the
nucleus
Since splicing of nascent mRNA occurs in the nucleus of the cell, an
effect of DFOon splicing efﬁciency should lead to an increase of aberrantly
spliced mRNA predominantly in the nucleus. To test this hypothesis, we
treated the K562 cells with 100 μM of DFO for 48 h and isolated RNA
from cytoplasm and nucleus separately. As shown in Fig. 3C, in the
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nucleus, the amount of aberrant FECHmRNA in DFO-treated cells was 4.5
times higher than that in untreated cells. In the cytoplasm, the DFO-
induced differencewas only 1.9 fold. The result was conﬁrmed in two ad-
ditional experiments. Thisﬁnding indicated that DFO treatment enhances
aberrant splicing of newly synthesized FECH mRNA.
Decrease of the amount of FECH protein after iron chelation
Next, we tested if the down regulation of correctly spliced FECH
mRNA under iron depletion is reﬂected by a decrease in the amount
of FECH protein. Again, we treated K562 cells with DFO (50, 100 and
200 μM), iron or a stoichiometric amount of both iron and DFO for
60 h and isolated proteins from the cytosolic and membrane fractions
separately. Equal amounts of protein from the membrane fraction,
where ferrochelatase is located, and from the cytosolic fraction, where
β-actin is located, were analyzed on Western-blot (Fig. 3D). The result
showed a strong decrease of FECH protein under the iron deﬁcient con-
dition, whereas FECH protein levels remained unchanged in samples
treated with either iron alone or with stoichiometric amounts of both
iron and DFO.
As the next step, we explored possible mechanism(s) by which
iron regulates the alternative splicing of FECH intron 3.
siRNA mediated silencing of splice factor U2AF65 leads to a decrease of
correctly spliced and an increase in aberrantly spliced FECH mRNA
Splicing of precursor mRNAs requires accurate recognition of splice
sites by the spliceosome, an assembly of small nuclear ribonucleoprotein
particles (snRNPs) and extrinsic (non-snRNP) protein splicing factors
[18]. The U2 snRNP auxiliary factor (U2AF) is an essential splicing factor
composed of two subunits. The large subunit of 65-kDa (U2AF65) binds
to the polypyrimidine tract (PY-tract) upstream from the 3′ splice site
and promotes U2 snRNP binding to the pre-mRNA [32,45]. Although
the small subunit U2AF35 is important for the splicing of introns that
contain short or weak PY-tracts, the recognition of a weak 3′ binding
site requires the interaction between the two subunits [14,32].
In intron 3 of the FECH gene, both the constitutive and aberrant
splicings contain an AG dinucleotide at their 3′ splice sites. However,
they differ in the strength of the Py-tract that precedes the 3′ splice
sites. As shown in Fig. 4, the aberrant splice site is preceded by a
23-nucleotide polypyrimidine-rich sequence including a stretch of 15
cytosines/thymines (Cs/Ts). In contrast, the Py-tract of the constitutive
splice site containsmostly short sequences of 3 or less Cs/Ts. Apparently,
enough correct FECH mRNA is generated, which indicates a sufﬁcient
recognition of the weak Py-tract, as reﬂected in the splice ratio between
normal and aberrant products.
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To study the action of splice factor U2AF65 on splicing of FECH intron
3, we targeted U2AF65 by siRNA and measured the splice ratio between
normal and aberrant products. As shown in the left panel of Fig. 5A,
transfection of K562 cells with different concentrations of siRNA against
U2AF65 resulted in 35.5% (10 nMsiRNA) to 48.7% (50 nMsiRNA) reduc-
tion in itsmRNA level. The difference between 0 nM (mock) and 50 nM
or 100 nM was statistically signiﬁcant, p b 0.05 (n = 3; the left
panel of Fig. 5A). With respect to the FECH transcripts, the correctly
spliced mRNA decreased from 72.2% (SD = 4.7%; mock) to 57.4%
(SD = 8.3%; 100 nM siRNA) of the total (the right panel of Fig. 5A).
The difference between 0 nM and 100 nM was statistically signiﬁcant,
p b 0.05 (n = 3). In parallel, the aberrant product increased from
27.8% (SD = 4.7%; mock) to 42.6% (SD = 8.3%; 100 nM siRNA) of the
total.
These data indicated that U2AF65 down regulationmimics the effect
of iron deprivation. Webby et al. recently reported that splice factor
U2AF65 is hydroxylated by the iron-, oxoglutarate (2OG)- and oxygen-
dependent dioxygenase Jumonji domain-containing protein 6 (Jmjd6)
[44]. Being iron-dependent, Jmjd6 could act as a sensor for iron avail-
ability and therefore might be the link between iron-deprivation and
splicing regulation. As a next step, we tested the putative involvement
of Jmjd6 in splicing of FECH intron 3.
siRNA mediated silencing of dioxygenase Jmjd6 decreases the correctly
spliced and increases the aberrantly spliced FECH mRNAs
Treatment of K562 cellswithdifferent concentrations of siRNAagainst
Jmjd6 led to 20.8% (SD = 3.5%; 10 nM siRNA) to 40.4% (SD = 7.5%;
30 nM siRNA) reduction in Jmjd6 mRNA (p b 0.01; Fig. 5B, the left
panel). Under these treatment conditions, the proportions of the correctly
spliced FECHmRNAdecreased from81.2% (SD = 2.2%;mocked) to 73.7%
(SD = 1.3%; 50 nM siRNA) of the total FECH transcripts and the aberrant
variant increased from 18.8% (mocked) to 26.3% (50 nM siRNA) of the
total transcripts (p b 0.001; n = 3; Fig. 5B, the right panel).
Although targeting the synthesis of a particular transcript by siRNA
is a highly speciﬁc approach, this technique only achieved an approxi-
mately 40% reduction in mRNA of both U2AF65 and Jmjd6. Since Jmjd6
does not directly inﬂuence FECH splicing, rather it exerts its action via
U2AF65, targeting Jmjd6 resulted in a small change in the amount of cor-
rectly spliced product i.e., from 81.2% to 73.7% (difference = 7.5%)
of the total, as compared to a larger change from 76.8% to 62.6%
(difference = 14.2%) when targeting U2AF65 directly. To maximize
the effect of Jmjd6 on FECH splicing, we conducted additional experi-
ments using less speciﬁc but more effective inhibitors of Jmjd6.
Inhibition of Jmjd6 by cobalt chloride (CoCl2) and by dimethyloxallyl glycine
(DMOG), an analogue of oxoglutarate
The activity of iron- and oxoglutarate dependent dioxygenases can
be inhibited by iron deprivation using chelators such as DFO or by
other divalent metal ions such as cobalt, which can compete with
iron. Alternatively, analogues of oxoglutarate such as DMOG, can
block the substrate binding site of the enzyme via competitive inhibi-
tion (For review see: [35]).
Treatment of K562 cells with CoCl2 (concentrations ranging from 50
to 200 μM) for 24 h resulted in a strong and dose-dependent decrease
of FECH mRNA and a concomitant increase in aberrant splice product
to 44.8% (SD = 8.8%; at 200 μM) of the total transcripts (p b 0.05;
Fig. 5C).
In the experiments with DMOG, we tested the levels of FECH tran-
scripts as well as ferrochelatase protein. Like with cobalt chloride, treat-
ment of K562 cells with DMOG (concentrations 2.5 mM and 5 mM) for
24 h resulted in a strong and dose-dependent decrease of FECH mRNA
and an increase in aberrant splice product to 51.8% (SD = 5.4%; at
5 mM) of the total (p b 0.001; Fig. 5D). In the Western blot analysis of
ferrochelatase from themembrane fraction of the cell lysate, the intensity
of bands decreased as the concentration of DMOG increased (Fig. 5E).
Discussion
The present study demonstrated an association between the avail-
ability of iron and regulation of alternative splicing of FECH intron 3.
Based on our results, we put forward the following hypothesis to
explain the underlying mode of action/mechanism (Fig. 6, upper
panel): In cells with a normal iron status, ferrous iron together with
substrates oxygen and 2-OG bind to Jmjd6. The dioxygenase Jmjd6
catalyzes the posttranslational lysyl-5-hydroxylation of U2AF65 [44].
The tandem RNA recognition motif domains (RRM) of U2AF65 exhibit
a broad range of conformations [17]. The RRM adopt two remarkably
distinct arrangements, i.e. closed and open ones, in the absence or
presence of a high afﬁnity PY-tract, respectively. The equilibrium be-
tween the two conformations functions as a molecular control unit
ATCTTGTTAGGCTCTCTAAAATTTTGCTTTTTTTCTTTTTTATTGAGTAG AAAACATTT
CTCAGGTTGCTAAGCTGGAATAAAATCCACTTACCTGTATGTTAAATGATTTAG TAAGC
strong polypyrimidine-tract
weak polypyrimidine-tract
exon 4
-1 intron 3
aberrant splice
acceptor site at
position-63 
-54
IVS3-48c/t
premature
termination
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-113 -55
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Fig. 4. A partial sequence showing the intron 3–exon 4 boundary of the FECH gene. The AG dinucleotides from both the constitutive splice site and an aberrant splice site at position−63
are in bold. Position−48 and a premature termination codon TAA at position−44 are in bold and underlined. T and C nucleotideswithin polypyrimidine tracts in front of both correct and
aberrant splice acceptor sites are underlined. The alternative splice site is preceded by a strong PY-tract containing 21 pyrimidines and two interspersing purines. The constitutive splice
site, on the other hand, is preceded by a weaker PY-tract which consists of mostly short sequences of three or less pyrimidines.
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that translates the natural variations in PY-tract nucleotide composi-
tion, length and functional strength into the efﬁciency of U2AF65 to
recruit U2snRNP to the spliceosome [30]. The conserved α-helical
surface of RRM 2 of U2AF65 that is only accessible in the open conﬁgu-
ration contains the lysyl residue K276, as it has been demonstrated by
Webby et al., is hydroxylated by Jmjd6 and upon hydroxylation, it alters
the splicing of certain genes [44]. Our study demonstrates that both
inhibition of Jmjd6 and siRNAmediated down-regulation of U2AF65 in-
duce a shift from correct to aberrant splicing of the FECH intron 3 (Fig. 6,
lower panel).
Jmjd6 belongs to a large family of iron- and 2OG-dependent
dioxygenase enzymes that are involved in numerousmetabolic activities
including collagen biosynthesis, fatty acid metabolism, DNA repair, RNA
and chromatinmodiﬁcations, and hypoxic sensing [35]. Our study estab-
lishes a link between one of the dioxygenases and heme biosynthesis
which by itself is closely associated with oxygen metabolism, as heme
is directly involved in oxygen transport and acts as a prosthetic group
of cytochromes.
Prior to Webby et al. who established for the ﬁrst time the connec-
tion between alternative splicing and oxygen and iron sensing via
Jmjd6, Kim et al. observed that under iron-deprived condition a splice
variant of spermidine/spermine N(1)-acetyltransferase mRNA in-
creased in several cell lines [22]. More recently, Boeckel et al. described
that treatment with siRNA against Jmjd6 resulted in an increase in the
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soluble form of Flt1, a product of alternative splicing, and a subsequent
inhibition of angiogenesis [5]. All three above-mentioned studies,
together with ours, demonstrated that the regulation of alternative
splicing by both iron deprivation and inhibition of Jmjd6 is involved in
a broad range of metabolic processes.
As stated before, iron deprivation caused an increase in aberrant
splicing and decreases of both FECH mRNA and protein. However,
this result was not in a total agreement with that of Taketani et al.
[40], who reported a decrease of only FECH protein and activity, but
not of FECH mRNA in K562 cells treated with 50–150 μM DFO for
16 h. More recently, Crooks et al. reported that iron deprivation
diminished the stability of newly formed FECH proteinwithout altering
the level of FECH mRNA or the mature protein [7]. FECH is an iron–
sulphur cluster containing protein and an intact iron sulphur cluster
is required for enzymatic activity [10]. Crooks et al. assumed that
under iron-deprivation the newly formed FECH lacks the iron–sulphur
cluster which explains the instability and rapid degradation. They con-
cluded that the effect of iron deprivation is similar to the disease
ISCU-myopathy, an inborn defective biosynthesis of iron sulphur
clusters with reduced FECH activity (OMIM 255125). In both studies,
however, the failure in detecting any reduction in FECH mRNA under
iron deprivation could be explained by the use of northern blot analysis
for the quantitative FECH mRNA determination which most likely is
unable to discriminate between the normal and aberrant splice products
since these two mRNA species differ only by 63 bp in size.
The inﬂuence of iron chelation by DFO on alternative splicing
depended on the genotype in the lymphoblastoid cell lines: The cell
line bearing the SNP type IVS3-48T/T which is the most frequent
in Caucasians showed the strongest increase in the amount of
aberrantly spliced mRNA under iron-deprived conditions. By contrast,
a much smaller increase in the amount of aberrant FECH transcript by
iron deprivation was observed in the cell lines with both the C/C and
M/C genotypes. Assuming that the described effect of iron deprivation
on splicing in the T/T genotype is a regulatory feature, the observed
loss in sensitivity in the IVS3-48C background constitutes a loss of
potential for regulation. Taking both together, the increase in aberrant
splicing under baseline condition and the lack of that increase under
iron deprivation indicate that even if there is enough iron available,
the C/C genotype behaves in a manner as if iron is deﬁcient.
The 3′ end of intron 3 of the FECH gene including the aberrant splice
site at position−63 and both PY tracts, is highly conserved among hom-
inids (Fig. 7). Among the available sequences of chimp, gorilla and
orangutan, only the T-variant at position −48 is documented, even if
we cannot exclude the possibility of the C-variant present at a low
frequency among the non-human species of hominids. However, this
is unlikely as Gouya et al. demonstrated that the C-variant appeared
in the human population about 60'000 years ago as a de-novo mutation
in humans and was not present in the original human FECH [12].
Based on the fact that the frequency of IVS3-48C varies considerably
among different populations, one might speculate that this large varia-
tion may be related to the availability of dietary iron. In a population
that is under chronic iron-deﬁcient conditions, regulation of iron
might be of less importance than in populations with sufﬁcient iron
supply. The Japanese population, for example, has a high prevalence
of the IVS3-48C genotype [12]. On the other hand, the dietary habits
of Japanese i.e., a relatively low intake of iron and high intake of
iron-absorption inhibitors such as green tea and soybeans make
them more vulnerable to iron deﬁciency compared to the Caucasian
population [4,42]. Therefore, the regulation of transcription of
ferrochelatase among Japanese might be less important compared
to that in Caucasians.
Based on the results of this study, we propose that availability of
iron regulates the activity of ferrochelatase by alternative splicing and
RUST. Iron-signaling involves Jmjd6, which modulates U2AF65-lysyl-
hydroxylation. This in turn, inﬂuences the relative amounts of correct
and aberrant FECHmRNA splice products and consecutively the amount
of FECH protein.
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Fig. 7. Comparison of partial FECH intron 3–exon 4 sequences among hominids. The exon 4 sequence is in bold, the polypyrimidine tracts are underlined and sequence elements
related to FECH intron 3 splicing are highlighted in gray. Conserved nucleotides are indicated by asterisk, among which are both constitutive and aberrant splice sites, both
weak and strong polypyrimidine tracts and the stop codon at position −44. At position −48 all hominids carry a T.
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The activity of the erythroid-speciﬁc isoenzyme of 5-aminolevulinic acid synthase (ALAS2), the ﬁrst and rate-
limiting enzyme in heme biosynthesis, is down-regulated during iron-deﬁciency. Ferrochelatase (FECH), the
last enzyme of this pathway, inserts iron into protoporphyrin IX (PPIX) to form heme. Patients with erythropoi-
etic protoporphyria (EPP), an inherited deﬁciency in FECH, often show signs of iron deﬁciency in addition to
phototoxicity which is caused by PPIX accumulation. However, iron supplementation often leads to exacerbation
of phototoxicity. We report three EPP patients who had reduced erythrocytic PPIX concentrations when they
were iron-deﬁcient and their microcytic and hypochromic anemia deteriorated. Additionally, we found a signif-
icant increase in the amount of ALAS2mRNA and protein among EPP patients. To verify the connection between
FECHdeﬁciency and ALAS2 over-expression,we inhibited FECH in cultured cells and found a subsequent increase
in ALAS2 mRNA. We conclude that the primary deﬁciency in ferrochelatase leads to a secondary increase in
ALAS2 expression. The combined action of these twoenzymeswithin thehemebiosynthetic pathway contributes
to the accumulation of PPIX. Furthermore, we hypothesize that EPP patients may beneﬁt from a mild iron
deﬁciency since it would limit PPIX production by restricting ALAS2 over-expression.
© 2014 Elsevier Inc. All rights reserved.
Introduction
The heme biosynthetic pathway consists of eight enzymes that
sequentially convert glycine and succinyl CoA to heme [35]. This path-
way is tightly regulated in order to prevent any accumulation of noxious
intermediates under physiological conditions [1,23]. The regulation is
achieved by the ﬁrst and rate-limiting enzyme in the pathway, 5-
aminolevulinic acid synthase (ALAS). This enzyme has two isozymes,
the housekeeping form ALAS1 and the erythroid-speciﬁc form ALAS2
[7,10,21,38]. The activity of ALAS1 in the liver is controlled by the end-
product heme via a negative feedback mechanism, whereas ALAS2 is
not regulated by heme [17,26,34]. Instead, iron is involved in the regu-
lation of ALAS2 activity at the translational level. The 5′-untranslated
region of ALAS2 mRNA contains an iron-responsive element (IRE) that
acts as a binding site for the IRE-binding proteins (IRPs) 1 and 2. A
low intracellular free iron-pool leads to the binding of IRP1 or 2 to IRE
which then blocks the translation of ALAS2 mRNA and in turn reduces
the amount of active enzyme formed [6,30,33].
Ferrochelatase (FECH) catalyzes the last step in the heme biosyn-
thetic pathway, the insertion of ferrous iron (Fe2+) into protoporphyrin
IX (PPIX) to form heme. In the case of a partial FECH deﬁciency, which
causes the hereditary disorder of erythropoietic protoporphyria (EPP,
OMIM #177000), the substrate PPIX, but not the cosubstrate iron,
accumulates in the body and causes symptoms of cutaneous phototoxic
reactions in these patients [12,24]. A similar accumulation of PPIX can
be the result of inherited ALAS2 hyperactivity, which is the underlying
cause of X-linked dominant protoporphyria (XLDPP, OMIM #300752)
with a clinical presentation indistinguishable from that of EPP [38].
The clinical observation of XLDPP indicates that when ALAS2, the rate-
limiting enzyme in erythroid heme biosynthesis, is overly active, the
FECH reaction becomes rate-limiting and as a result, PPIX accumulates.
In addition to PPIX accumulation, iron metabolism is disturbed in
EPP, as a signiﬁcant proportion of the patients show signs of iron
deﬁciency including a low serum iron and ferritin concentration andmi-
crocytic and hypochromic anemia [14,19,36,40]. However, iron supple-
mentation has been seen to exacerbate the skin symptoms in a number
of patients— a paradox that could not be explained so far [5,25,29]. In a
minority of patients with protoporphyria, a beneﬁcial effect of iron
supplementation has been reported [18,22]. Since all case reports but
one, were published prior to the discovery of XLDPP, the possibility
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that some of the described subjects suffered from XLDPP instead of EPP,
exists. As different pathophysiologies are involved in these two
disorders, XLDPP and EPP patients might react differently to iron
supplementation.
In this study, we present clinical observations on exacerbation of a
microcytic, hypochromic anemia (a biological expression of iron deﬁ-
ciency) and a concomitant decrease of protoporphyrin levels in three
EPP patients, which indicates that iron may have a regulatory effect on
protoporphyrin accumulation in EPP. Because ALAS2 activity is regulat-
ed by iron, we quantiﬁed the amount of both ALAS2 mRNA and ALAS2
protein in peripheral blood samples from EPP patients and compared
their levels with those from control subjects. In addition, we conducted
in vitro experiments to measure the level of ALAS2 mRNA after inhibi-
tion of FECH. By putting all three elements together, FECH deﬁciency,
ALAS2 expression and iron availability, we propose an extended
model to explain the pathophysiology of EPP.
Materials and methods
Subjects
Three EPP patients from our outpatient clinic are described in detail
with respect to their clinical presentation and laboratory ﬁndings. In
addition, we studied 17 clinically and genetically diagnosed EPP pa-
tients and twenty non-porphyric subjects. This study was approved by
the local ethics committee and was conducted in concordance with
the Helsinki declaration. Written informed consent was obtained from
all subjects. Peripheral blood samples were collected in PAXgene
Blood RNA tubes and DB Vacutainer® CPT™ tubes from these individ-
uals for isolation of total RNA and protein, respectively. Reticulocyte
count and hydroxymethylbilane synthase (HMBS) activity were
measured in EDTA- and heparin-anticoagulated blood samples,
respectively.
Laboratory analyses
Erythrocyte indices, serum iron, transferrin saturation and soluble
transferrin receptor (sTfR), reticulocyte count, and erythrocyte PPIX
concentrationwere performed as routine analyses either at the Institute
of Laboratory Medicine, Triemli Hospital or at the Institute of Clinical
Chemistry, University Hospital of Zürich, Switzerland. HMBS activity
measurements were conducted at the Institute of Laboratory Medicine,
Triemli Hospital according to a published protocol [32].
Chemicals and reagents
N-methyl protoporphyrin (NMPP) was purchased from Sigma-
Aldrich (St. Louis, Missouri, USA). A 1 mM stock solution of NMPP was
prepared by dissolving the substance in a 20 mM NH4OH (Sigma--
Aldrich) solution containing 2% Tween 20 (Sigma-Aldrich). The same
solvent (20 mM NH4OH and 2% Tween 20) was used for preparation
of different working solutions with concentrations ranging from 2.5 to
10 μM in a ﬁnal volume of 60 μl. Butylated hydroxytoluene (BHT) was
purchased from Sigma-Aldrich and resolved in ethanol (96–100%) to a
concentration of 100 μg/ml (stock solution) and was used in the cell
culture at a ﬁnal concentration of 0.5 μg/ml.
Cell culture
The human erythroleukemic K562 cell line (American Type Culture
Collection) was cultured in RPMI 1640 medium (Gibco, Invitrogen,
Carlsbad, California, USA) supplemented with 10% fetal calf serum
(Bioconcepts Amimed, Allschwil, Switzerland) and streptomycin/peni-
cillin (Gibco, Invitrogen) at 37 °C under 5% CO2. The cells were split
1:5 every third day to maintain an exponential growth phase. For each
experiment, 100,000 cells were washed with medium without
antibiotics and seeded in a 6-well cluster plate containing 6 ml fresh
medium. The cells were treated with different concentrations (0, 2.5, 5
and 10 μM) of NMPP and incubated for eight days [3,20]. As controls,
non-treated cells, cells treated with solvent, BHT (antioxidant) or
ethanol only and cells treated with both solvent and BHT were used.
After four days, the medium was refreshed. All measurements were
conducted in duplicates. The experiment was repeated three times.
RNA isolation and RT-PCR
Total RNA was extracted from peripheral blood samples by the
PAXgene Blood RNA Kit (PreAnalytiX GmbH, Hombrechtikon,
Switzerland) according to the manufacturer's protocol. Total RNA was
isolated from cultured cells by using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer's protocol including
the optional on-column DNase digestion step. The quality of RNA was
evaluated using RNA Nano chips on an Agilent 2001 bioanalyzer
(Agilent Technologies, Santa Clara, California, USA). RNA was then
quantiﬁed on a Nanodrop 2000c Spectrophotometer (Thermo Fisher
Scientiﬁc, Waltham, Massachusetts, USA). One-thousand nanograms
of total RNA from each isolation were reverse transcribed into
cDNA by using the Transcriptor First Strand cDNA Synthesis Kit
and anchored-oligo(dT)18 primer (Roche Diagnostics Inc., Basel,
Switzerland).
For quantiﬁcation of cDNA, real-time PCR was performed on an
ABI PRISM 7000 using gene speciﬁc primers and TaqMan probes
(ALAS2, Hs01085694_m1; FECH, Hs01555261_m1 and beta-actin,
Hs99999903_m1; Applied Biosystems, Life Technologies, Carlsbad,
California, USA). One-twentieth of the resulting cDNA was used in
each reaction. All measurements were done in triplicates. To obtain
the relative concentration of either FECH or ALAS2, the threshold
cycle (Ct) value of these transcripts was subtracted by that of β-
actin (ΔCt). The concentration was expressed in arbitrary unit
(a.u.) as 2−ΔCt × 103.
Western blot analysis
Peripheral blood samples (8ml)were collected into BD Vacutainer®
CPT™ tubes containing 2 ml Ficoll and 1 ml 0.1 M sodium citrate
(Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The tube
was centrifuged within 2 h after blood collection at 3000 rpm for
25 min which separates mononuclear cells, granulocytes and erythro-
cytes based on their density. After centrifugation, 200 μl of the upper
layer of the red blood cell fraction which contains mainly reticulocytes
and young erythrocytes, were carefully collected. In addition, 200 μl of
the mononuclear cell fraction was collected. Both cell fractions were
washed twice with PBS and used for protein isolation.
For isolation of the cytosolic and membrane protein fractions of the
cells Qproteome Cell Compartment Kit (Qiagen) was used according to
the manufacturer's protocol. Western blot analysis was conducted ac-
cording to a previously described protocol with slight modiﬁcations
[5]. The protein concentration in the fractions was determined by the
benzethonium chloride method on a clinical chemistry analyzer,
Cobas 501 (TPUC3; Roche Diagnostics Inc., Rotkreuz, Switzerland). In
theWestern blot analysis, an equal amount of protein from each sample
was loaded on the gel. For the detection of ALAS2 protein, ALAS2 prima-
ry antibody (D4 sc166739 in 1:200 dilution) and secondary antibody
goat anti mouse IgG-HRP (sc2005 in 1:2000 dilution; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) were used. The ALAS2 protein
was visualized by staining the membranes with Sigma FAST DAB
horse radish peroxidase substrate as previously described [5]. The in-
tensity of ALAS2 bands was densitometrically quantiﬁed with the
Image J-software (http://rsbweb.nih.gov/ij/download.html) which
gives numerical readings (arbitrary units, a.u.).
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Table 1
Erythrocyte indices and iron status in three EPP patients.
HGB
(♀12.0–15.4 g/dL;
♂14.0–18.0 g/dL)
HCT
(36–45%)
RBC
(♀3.9–5.15 × 1012/L;
♂4.5–5.9 × 1012/L)
MCV
(♀80–99 fL;
♂82–89 fL)
MCH
(♀27–34 pg/RBC;
♂28–32 pg/RBC)
Soluble TfR
(patients 1 and 3:
0.76–1.76 mg/L)
(patient 2: 1.9–4.4 mg/L)
Free PPIX
(b0.20 μmol/L RBC)
Iron
(6.6–26.0 μmol/L)
Transferrin saturation
(23–46%)
ferritin
(13–150 μg/L)
Patient 1
02.10.2012 11.9 38 4.47 84 27 n.a. 21.1 n.a. n.a. n.a.
11.01.2013 12.2 39 5.04 78 24 n.a. 21.0 n.a. n.a. n.a.
15.03.2013 9.5 32 4.62 70 21 n.a. 5.5 n.a. n.a. n.a.
09.04.2013 9.9 33 4.89 67 20 4.43 n.a. n.a. n.a. n.a.
Patient 2
08.08.2007 n.a. n.a. n.a. n.a. n.a. n.a. 26.6 n.a. n.a. n.a.
02.05.2011 11.2 34 4.8 72 23 9.5 37.0 3.1 3 10
19.06.2012 11.0 33 4.66 70 24 n.a. 49.3 n.a. n.a. n.a.
18.09.2012 10.8 34 4.88 69 22 n.a. 29.6 n.a. n.a. n.a.
04.03.2013 10.6 33 4.73 69 22 n.a. 29.9 2.2 3 3
17.04.2013 10.2 31 4.56 69 22 n.a. 21.8 3.0 3 5
27.06.2013 9.2 38 4.24 67 22 11.45 22.8 3.0 8 3
02.07.2013 10.1 31 4.67 67 22 10.79 24.0 56.5 64 6
09.07.2013 10.7 34 5.08 67 21 11.63 18.0 5.5 6 5
19.07.2013 9.5 30 4.4 67 22 10.9 22.1 2.2 3 4
Patient 3
28.06.2000 13.9 n.a. n.a. n.a. n.a. n.a. 28.2 n.a. n.a. n.a.
24.11.2009 13.6 n.a. n.a. n.a. n.a. 1.22 27.1 n.a. n.a. n.a.
30.05.2012 12.5 n.a. n.a. n.a. n.a. n.a. 11.0 n.a. n.a. n.a.
05.06.2013 13.1 n.a. 5.22 76 25 n.a. 16.8 n.a. n.a. n.a.
Reference ranges are given in parentheses. Abnormal values are in bold.
HGB, hemoglobin; HCT, hematocrit; RBC, red blood cell count; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; sTfR, soluble transferrin receptor; PPIX, protoporphyrin IX.
n.a., not available.
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Statistical analysis
Data were analyzed by either Mann–Whitney U test or Pearson
product–moment correlation coefﬁcient (VassarStats, Richard Lowry,
www.vassarstats.net). A one-sided p≤ 0.05was considered to be statis-
tically signiﬁcant.
Results
Case reports
Patient 1
An 18-year-old female EPP patient suffered from photosensitivity
since early childhood. In addition, she intermittently showed clinical
symptoms of iron deﬁciency including fatigue and dizziness that were
accompanied by a drop in hemoglobin levels. She had no increased
menstrual bleeding or any additional blood loss. However, her regular
diet was low on iron. In the late summer of 2012, she received intrave-
nous iron supplementation from her family physician. Shortly thereaf-
ter, she complained about worsening of the skin symptoms and
visited our outpatient clinic in October.
Because of the exacerbation of EPP symptoms, we advised her to
stop iron supplementation. In the spring of 2013, the symptoms of
fatigue and dizziness returned. At this time, erythrocyte indices showed
microcytosis and hypochromia with a hemoglobin concentration of
9.5 g/dL. In addition, her soluble transferrin receptor (sTfR) was
increased, indicating an iron deﬁciency during formation of new eryth-
rocytes. The protoporphyrin concentration dropped from 21 μmol/L in
January to 5.5 μmol/L in March. In April of 2013, she received another
round of intravenous iron substitution from her family physician and
her EPP symptoms got worse again. However, PPIX was not measured
at this time (Table 1).
Patient 2
A 35-year-old female suffered from phototoxic reactions after sun-
light exposure since the age of 2.5 years. The diagnosis of EPP was
established at the age of 28. She began to regularly visit our outpatient
clinic since 2007. Her blood test had been showingmicrocytic and hypo-
chromic anemia over the years. From time to time she experienced
symptoms indicating iron deﬁciency such as, fatigue and difﬁculty to
concentrate on her work. In the summer of 2013, the clinical symptoms
of iron deﬁciency intensiﬁed, likely due to frequent blood drawings for
unrelated reasons. Iron deﬁciency was underlined by a drop in her
hemoglobin concentration (9.2 g/dL) and an increase in the sTfR con-
centration. She was given oral iron substitution starting on June 28th,
2013 at a dosage of 105mg per day (KENDURAL, Teofarma Inc., Lugano,
Switzerland). Five days later, on July 2nd, the treatment was
discontinued because of elevated liver enzymes. The patient noticed a
slight increase in sunlight sensitivity after the 5-day iron supplementa-
tion. The increased sunlight sensitivity lasted one week. While PPIX con-
centration rose moderately from 22.8 to 24.0 μmol/L during this 5-day
period, her hemoglobin level increased from 9.2 g/dL to 10.1 g/dL.
Three weeks after the iron supplementation, her hemoglobin level
dropped to 9.5 g/dL, whichwas close to the pre-treatment concentration.
Patient 3
A 51-year-old male was diagnosed with EPP at the age of 7 after se-
vere phototoxic attacks following sunlight exposure since the age of 3.
Over the past 13 years, hewas tested occasionally for PPIX, hemoglobin
and ironmetabolism parameters (Table 1). Despite decreased hemoglo-
bin concentrations, he never received iron supplementation.
Low iron status and correlation between iron availability and PPIX in EPP
The hemoglobin concentrations of all three patients laid either close
to the lower limit of normal range or below the normal range (Table 1).
The decreased hemoglobin concentrations were accompanied by
microcytosis and hypochromia, as shown by lowmean corpuscular vol-
ume (MCV) and lowmean corpuscular hemoglobin (MCH) values. sTfR
was increased during the periods of exacerbated anemia, indicating iron
deﬁciency. In addition, patient 2 also showed low serum iron, transfer-
rin saturation and ferritin values. Within each patient, the erythrocytic
PPIX concentrations correlated signiﬁcantly with that of hemoglobin,
i.e. during periods of iron-deﬁcient anemia, the erythrocytic PPIX con-
centration was lower than that during periods when iron was
replenished (Fig. 1). The dependence of PPIX accumulation onhemoglo-
bin level was nominally unique for each individual patient and not com-
parable among them.
Increase in ALAS2 expression among EPP patients
As stated in the Introduction section, ALAS2 activity is rate-limiting
in the biosynthesis of erythroid heme and is regulated by iron availabil-
ity. We therefore measured the amount of ALAS2 protein in the young
erythrocytes from EPP patients and healthy controls by Western blot
analysis. Since reticulocytes and young erythrocyts have lower speciﬁc
weight than mature erythrocytes, they reside in the top layer after
gradient-centrifugation of blood samples in Ficoll [8]. These young
erythrocytes still contain proteins andmRNA for the heme biosynthesis
enzymes. As under our experimental conditions, no beta-actin was de-
tected in either cytosolic or membrane fractions of young erythrocytes
and mononuclear cells by the Western blot analysis (data not shown),
we used total protein concentration as a reference instead of beta-
actin. A band corresponding to the correct size of ALAS2 was visible in
theWestern blot analysis of the cytosolic fraction of young erythrocytes
(Fig. 2). No ALAS2 was detected by the same Western blot analysis in
the membrane fraction of young erythrocytes. As in both the cytosolic
and membrane fractions of mononuclear cells no ALAS2 was detected
(data not shown), this result indicated that the antibody against
ALAS2 does not cross-react with ALAS1 in the Western blot analysis.
Subsequently, we determined the amount of ALAS2 protein in the sam-
ples from 5 EPP patients and 5 control subjects by densitometric scan-
ning of the blot. The result showed a signiﬁcant difference between
patients (mean= 14,903 a.u., SD= 8288 a.u., n = 5) and control sub-
jects (mean = 6200 a.u., SD = 5135 a.u.; p ≤ 0.05) ie, ALAS2 protein
was about two times higher in the enriched young erythrocytes from
EPP patients compared to those from healthy volunteers (Fig. 3).
ALAS2mRNA contains an IRE element and its translation is inhibited
under iron-deﬁcient conditions [6,30,33]. Since EPP patients display
signs of iron deﬁciency, one would expect a decrease in ALAS2 protein
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Fig. 1. Correlation between erythrocyte free protoporphyrin IX and hemoglobin concen-
trations in EPP. The concentration of free PPIX is plotted against that of hemoglobin
from patient 1 (■), patient 2 (▲) and patient 3 (●). The numerical values are listed chro-
nologically in Table 1. The correlation coefﬁcients are r= 0.99, p= 0.034, n=3 in patient
1; r= 0.61, p= 0.04, n = 9 in patient 2; and r= 0.981, p= 0.0096, n = 4 in patient 3.
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in these individuals compared to controls. However, an opposite effect
was observed in our small cohort. To further explore this observation,
we quantiﬁed the amount of ALAS2 mRNA in peripheral blood samples
of 15 EPP patients and 20 healthy volunteers. As shown in Fig. 3, nine of
the 15 patients had ALAS2 mRNA concentrations of ≥600 a.u. (median
782.7 a.u.; interquartile range: 329.0–948.7 a.u.). Among the 20 control
subjects, 14 had ALAS2 mRNA concentrations of ≤300 a.u. (median
194.8 a.u.; interquartile range: 90.9–360.0 a.u.). The difference in
ALAS2 mRNA concentration between EPP patients and control subjects
was statistically highly signiﬁcant (p b 0.001)with themedian fromEPP
patients being about 4 times higher than that from normal controls.
No difference in the age of circulating erythrocytes between patients and
controls
Erythrocyte precursors synthesize mRNA and protein during their
development in the bonemarrow. Before these precursors are extruded
from the bonemarrow into blood circulation, they lose both their nucle-
us and mitochondria, which renders them unable to synthesize mRNA
and consequently proteins. During the ﬁrst few days in circulation,
they lose their residual RNA and later on, during their lifetime in circu-
lation, the residual enzyme activities drop progressively [2]. Thus, the
increase in ALAS2 protein and mRNA in the blood samples of EPP pa-
tients could either be caused by an increased expression of the enzyme
during the development of erythrocytes in the bone marrow or be due
to a lower mean age of erythrocytes in the blood circulation of EPP pa-
tients compared to controls. For example, an increased rate of erythro-
poiesis as the result of a subclinical hemolysis could be suspected. To
investigate the latter possibility, we quantiﬁed the percentage of reticu-
locytes in the blood samples of eight EPP patients and seven healthy
controls. In the case of a stimulated erythropoiesis, we would expect
an increase in reticulocytes in the EPP blood samples. As shown in
Fig. 4 (upper panel), the percentage of reticulocytes was 0.70%, SD =
0.30 (n = 8) in EPP patients and 0.81%, SD = 0.35 (n = 7) in healthy
controls. The difference was not statistically signiﬁcant.
In addition, we measured enzymatic activity of hydroxymethylbilane
synthase (HMBS, another enzyme of heme biosynthesis) in washed
erythrocytes from peripheral blood samples of EPP patients and
healthy controls, and as an additional control, in samples from
patients with acute intermittent porphyria (AIP) who have approxi-
mately half of the HMBS activity. HMBS in erythrocytes is synthesized
during their development in the bone marrow only and remains
active in youngerythrocytes [2]. An increased proportion of young
erythrocytes in the peripheral blood would therefore lead to increased
activity of HMBS [2]. As shown in Fig. 4 (lower panel), the HMBS
activity (reference range: 66–126 pmol/mgHb/h) of EPP patients was
95.3, SD = 21.6 (n = 7) and that of the healthy controls 99.6, SD =
27.8 (n = 20) — the difference was not statistically signiﬁcant. As ex-
pected, theHMBS activity of AIP patients was around 50% of that of con-
trol subjects i.e., 44.9, SD = 9.0 (n = 16; p ≤ 0.0001; Fig. 4, lower
panel).
These results demonstrated that the observed difference in the
amount of both ALAS2 mRNA and protein between EPP patients and
control subjectswas not due to a difference in the age of their circulating
erythrocytes.
Inhibition of FECH enzyme leads to an increase in ALAS2 mRNA in the K562
cell line
The question remained, why is ALAS2 over-expressed in young
erythrocytes of EPP patients? Our hypothesis is that a deﬁcient FECH
could directly or indirectly enhance ALAS2 expression. To test this hy-
pothesis, we incubated the erythroleukemic K562 cells with N-methyl
protoporphyrin (NMPP). NMPP is a transition-state analogue of PPIX
and a potent inhibitor of FECH, which has been used to induce hemede-
ﬁciency in mammalian cell lines [3,37]. Treatment of K562 cells with
NMPP in a concentration range of 2.5–10.0 μMdid not cause signiﬁcant
changes in FECH mRNA. However, the amount of ALAS2 mRNA in-
creased up to two-fold after the NMPP treatment (Fig. 5).
Discussion
About a third of EPP patients show mild anemia featuring
hypochromia and microcytosis, frequently combined with low
serum iron and ferritin [14,19,36,40]. In non-porphyric subjects, this
type of anemia is a well-known sign of iron deﬁciency. On the other
hand, the residual FECH activity in EPP is only 35%, which may limit
heme synthesis and subsequently lead to anemia. However, other ane-
mias due to reduced heme synthesis such as that induced by lead poi-
soning, are not microcytic and hypochromic. Therefore, the question
arises as to which extent the anemia in EPP is due to iron deﬁciency
or to reduced heme synthesis. In this regard, of interest is the observa-
tion that an abnormal distribution of body iron, rather than an iron de-
ﬁciency, was found in an EPP mouse model [25]. This would indicate
that the availability of iron for erythropoiesis could be reduced in EPP.
Earlier studies in human EPP patients showed that stainable iron in
bone marrow was scarce, which also indicated a lack of iron available
for hemoglobin synthesis [39]. Moreover, if iron supplementation is
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beneﬁcial in EPP, an iron deﬁcit can be assumed. In the medical litera-
ture there are conﬂicting case reports on the effect of iron supplementa-
tion on EPP symptoms [4,18,27,31]. In our clinical experience, iron
supplementation has consistently exacerbated EPP phototoxic symp-
toms, although it may improve the general well-being of the patients,
increase their hemoglobin concentrations and thus ameliorate their
anemia. In the case of an inherited deﬁciency of FECH activity, the lack
of iron, a cosubstrate of FECH, could theoretically limit its capacity and
thereby enhance the accumulation of protoporphyrin IX and in turn, ag-
gravate the phototoxic symptoms. Iron supplementation in the case of
iron deﬁciency should therefore improve EPP symptoms. The question
iswhydoes our clinical observation contradict the expectedmechanism
of enzymatic action?
Two of the three cases thatwe presented here underline the fact that
there is a lack of biologically available iron for erythropoiesis in some
EPP patients, as revealed by increased soluble transferrin receptor and
low hemoglobin values. This iron deﬁciency measured as decreased he-
moglobin concentrations correlated signiﬁcantly with a reduced proto-
porphyrin concentration in erythrocytes. Such correlation was most
obvious in patient 2, as she had low serum concentrations of iron and
ferritin, decreased transferrin saturation and abnormal hematologic in-
dices including low hemoglobin, hematocrit, MCV and MCH. All three
patients showed the same tendency i.e., the lower the hemoglobin,
which we assume is a marker for biologically available iron, the less
PPIX accumulation in erythrocytes, and vice versa. These observations
led us to conclude that iron deﬁciency reduces the biosynthesis of pro-
toporphyrin through a regulated process. Our further study on ALAS2
shows that this rate-limiting enzyme of erythrocytic heme synthesis is
likely involved in this process. We found a signiﬁcant increase in both
mRNA and protein of the erythrocytic ALAS2 in EPP patients compared
to controls. An enhanced expression of ALAS2, in addition to FECH
deﬁciency, likely contributes to the extent of elevation of erythrocytic
PPIX seen in EPP patients. If iron becomes scarce, iron responsive pro-
teins 1 and 2 (IRP1, IRP2) bind to the iron response element (IRE) in
the mRNA of ALAS2 [9,11,13,16]. This binding is thought to reversibly
prevent the translation of ALAS2 mRNA [6,30]. Instead of the expected
reduction in translation, we found an increase in ALAS2 protein in EPP
blood samples. However, the increase in ALAS2 protein was less pro-
nounced than that in mRNA, which indicates that the translational
block due to the low iron is partially in place. This theory can be used
to explain the clinical observation on worsening of light sensitivity
under iron therapy as seen in many patients: The increased availability
of iron by supplementation releases the translational block on the ele-
vated ALAS2 mRNA, and the newly formed enzyme further increases
PPIX production. For ethical reasons, especially because of the risk of
liver damage, iron cannot be given to patients experimentally in order
to observe the full magnitude of PPIX increase. However, the available
data from the three patients presented here did show a parallel in-
crease/decrease in PPIX concentration and hemoglobin value, which
we assume, is an indirect measure for iron availability.
As mentioned above, the increases in ALAS2 mRNA and especially
ALAS2 protein could not be explained by the known mechanism of
iron regulation. This led us to further speculate that ALAS2 expression
may be inﬂuenced directly or indirectly by FECH. To test this hypothesis,
we conducted in vitro experiments in the erythroleukemic K562 cell
line using NMPP to interfere with FECH activity in order to mimic the
in vivo situation in EPP patients. Indeed, ALAS2 mRNA increased signif-
icantly during NMPP-induced inhibition, whereas FECH mRNA did not
change. Our in vitro results are in concordance with earlier ﬁndings by
Inafuku et al. [19], who induced an experimental EPP inmice by feeding
the animals with griseofulvin, a substance which is converted to NMPP
in the liver. The authors found a two-fold increase in the ALAS2 mRNA
but no change in the FECH mRNA in these mice after eight days of
feeding.
Our current model for the regulation of heme biosynthesis in EPP
during erythropoiesis is the following: the inherited deﬁciency of
FECH leads to an over-expression of ALAS2 in developing erythrocytes.
This overactive enzymewill contribute to PPIX accumulation in addition
to that caused by FECH deﬁciency. The frequently observed iron deﬁ-
ciency in EPP patients limits ALAS2 over-expression and thereby re-
stricts the amount of PPIX accumulation. The extent of PPIX
accumulation not only inﬂuences the severity of phototoxic symptoms,
but may also affect the risk of complicating liver damage [15,28,29]. In
this respect a slight shortage in iron could be beneﬁcial to EPP patients
and therefore, iron should be supplemented only when the symptoms
of iron deﬁciency becomes incapacitating.
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Fig. 4. Reticulocyte count in EPP patients and healthy controls (upper panel). The mean
and SD of the percentage of reticulocytes in the whole blood samples of EPP patients
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Fig. 5. Quantiﬁcation of FECH and ALAS2 mRNA from K562 cells treated with N-methyl
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